Form S-3

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

0001193125-13-355697.txt : 20130903 0001193125-13-355697.hdr.sgml : 20130902 20130903172317 ACCESSION NUMBER: 0001193125-13-355697 CONFORMED SUBMISSION TYPE: S-3 PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20130903 DATE AS OF CHANGE: 20130903 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001293310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770557236 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-190972 FILM NUMBER: 131075788 BUSINESS ADDRESS: STREET 1: 260 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.243.3100 MAIL ADDRESS: STREET 1: 260 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 S-3 1 d590927ds3.htm FORM S-3 Form S-3

As filed with the Securities and Exchange Commission on September 3, 2013.

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

KaloBios Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

77-0557236

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

260 East Grand Avenue

South San Francisco, CA 94080

(650) 243–3100

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

David Pritchard

Chief Executive Officer

KaloBios Pharmaceuticals, Inc.

260 East Grand Avenue

South San Francisco, CA 94080

(650) 243–3100

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Bennett L. Yee, Esq.

Richard C. Blake, Esq. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 1200 Seaport Boulevard Redwood City, CA 94063 (650) 321-2400

Approximate date of commencement of proposed sale to the public: From time to time, after the effective date of this Registration Statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ¨

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: x

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ¨

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box: ¨

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box: ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

CALCULATION OF REGISTRATION FEE



Title of Each Class of Securities to be Registered	Amount To Be Registered (1)	Proposed Maximum Offering Price Per Unit/Proposed Maximum Aggregate Offering Price (1)(2)	Amount of Registration Fee (3)
Common Stock, $0.001 par value per share (“Common Stock”) (4)	—	—	—
Warrants	—	—	—
Units	—	—	—
Total Offering	$100,000,000	$100,000,000	$13,640.00

Total Registration Fee			$13,640.00

(1)	An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices.

(2)

The proposed maximum per unit and aggregate offering prices per class of securities with respect to the primary offering will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered under this registration statement and is not specified as to each class of security pursuant to General Instruction II.D of Form S-3 under the Securities Act.

(3)	Calculated pursuant to Rule 457(o) under the Securities Act with respect to the primary offering.

(4)	Includes an indeterminate number of shares of common stock as may be sold from time to time, at indeterminate prices.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

EXPLANATORY NOTE

This registration statement contains two prospectuses:

•

a base prospectus which covers the offering, issuance and sale by us of up to $100,000,000 of our common stock, warrants and/or units; and

•

a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $50,000,000 of our common stock that may be issued and sold under a sales agreement with MLV & Co. LLC.

The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. The $50,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $100,000,000 of securities that may be offered, issued and sold by us under the base prospectus.

The information in this prospectus is not complete and may be changed. We may not sell the securities pursuant to this prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED SEPTEMBER 3, 2013

PROSPECTUS

LOGO

$100,000,000

KALOBIOS PHARMACEUTICALS, INC.

BY THIS PROSPECTUS, KALOBIOS MAY OFFER, FROM TIME TO TIME:

COMMON STOCK

WARRANTS

UNITS

KaloBios may offer and sell from time to time, in one or more series or issuances and on terms that KaloBios will determine at the time of the offering, any combination of the securities described in this prospectus, up to an aggregate amount of $100,000,000.

We will provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby.

These securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation and any over-allotment options held by them will be described in the applicable prospectus supplement. See “Plan of Distribution.”

Our common stock is listed on The NASDAQ Global Market under the symbol “KBIO.” We will provide information in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock on any securities exchange.

INVESTING IN OUR SECURITIES INVOLVES SIGNIFICANT RISKS. SEE “RISK FACTORS” BEGINNING ON PAGE 4 OF THIS PROSPECTUS AND IN THE APPLICABLE PROSPECTUS SUPPLEMENT BEFORE INVESTING IN ANY SECURITIES.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus is , 2013

TABLE OF CONTENTS


	Page
ABOUT THIS PROSPECTUS		1
PROSPECTUS SUMMARY		2
RISK FACTORS		4
FORWARD-LOOKING STATEMENTS		4
USE OF PROCEEDS		6
DESCRIPTION OF CAPITAL STOCK		7
DESCRIPTION OF WARRANTS		9
DESCRIPTION OF UNITS		10
PLAN OF DISTRIBUTION		11
LEGAL MATTERS		14
EXPERTS		14
WHERE YOU CAN FIND ADDITIONAL INFORMATION		14
INFORMATION INCORPORATED BY REFERENCE		15

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Under this shelf process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total amount of $100,000,000.

This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add to, update or change information contained in the prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded by the information in the prospectus supplement.

The prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities offered; the public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the offering of the securities.

You should only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make any representations in connection with this offering other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits.

You should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the information appearing in this prospectus, any prospectus supplement or any document incorporated by reference is accurate only as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects may have changed since that date.

PROSPECTUS SUMMARY

This summary description about us and our business highlights selected information contained elsewhere in this prospectus or incorporated in this prospectus by reference. This summary does not contain all of the information you should consider before buying securities in this offering. You should carefully read this entire prospectus and any applicable prospectus supplement, including each of the documents incorporated herein or therein by reference, before making an investment decision. As used in this prospectus, “we,” “us,” “KaloBios” and “our” refer to KaloBios Pharmaceuticals, Inc., a Delaware corporation.

KaloBios Pharmaceuticals, Inc.

Overview

We are a biopharmaceutical company focused on the development of monoclonal antibody therapeutics to treat serious medical conditions with a primary clinical focus on severe respiratory diseases and cancer. Using our proprietary and patented Humaneered^® antibody technology, we have produced a portfolio of patient-targeted, first-in-class, antibodies. We take a patient-targeted approach with each of our antibody programs by developing a new or utilizing an existing screen or diagnostic method that we believe may identify those individuals most likely to benefit from our therapies. We believe that antibodies produced with our Humaneered^® technology offer important clinical and economic advantages over antibodies generated by other methods, making our antibodies potentially more suitable for chronic treatment. We seek to identify and develop products that may treat multiple indications through proof-of-concept studies, and then secure development partnerships with large pharmaceutical and biotechnology companies who will further develop and commercialize our products while we retain rights in specialty or orphan indications.

We currently have three monoclonal antibodies at the clinical development stage:

•

Our first antibody, KB003 (a Humaneered^®, recombinant, anti-granulocyte macrophage colony-stimulating factor (anti-GM-CSF) monoclonal antibody), is in a Phase 2 clinical trial in severe asthma patients inadequately controlled by corticosteroids. We plan to report data from this trial by early 2014. KB002, the chimeric precursor molecule to KB003, showed activity with a single dose in a Phase 1/2 clinical study in persistent asthma and in a Phase 1 clinical study in rheumatoid arthritis (RA).

•

Our second antibody, KB001-A (a Humaneered^®, recombinant, PEGylated, anti-PcrV of Pseudomonas Fab’ antibody), is in clinical development for the prevention and treatment of infections caused by Pa, a gram-negative bacterium. Pa can cause chronic respiratory infections in individuals with cystic fibrosis (CF) and pneumonia in mechanically ventilated patients. Clinical trials in Pa VAP and CF patients infected with Pa were completed with a precursor molecule, KB001, that showed activity in Phase 1/2 clinical studies with a single dose for both indications.

•

KB001-A is in a Phase 2 clinical trial, conducted by us, in CF patients with chronic Pa lung infection. Clinical data are expected by the end of 2014. Our partner, Sanofi Pasteur (Sanofi), has an option to assume primary worldwide responsibility for developing and promoting KB001-A for Pa in CF or bronchiectasis patients after the completion of this Phase 2 clinical trial.

•

For the pneumonia prevention indication, Sanofi is conducting a Phase 1 clinical trial in healthy volunteers to evaluate higher doses than those previously tested. After completion of manufacturing process development and scale-up, Sanofi plans to conduct a Phase 2b trial in the first half of 2015 to determine the safety and efficacy of KB001-A in preventing Pa VAP. We understand that this Phase 2b and Phase 3 trial are being designed as pivotal trials and are intended to serve as a basis for registration of KB001-A in the prevention of Pa VAP.

•

Our third antibody, KB004 (a Humaneered^®, recombinant anti-EphA3 receptor tyrosine kinase monoclonal antibody), is in the dose escalation portion of a Phase 1 clinical trial in patients with hematologic malignancies. We plan to initiate the Phase 2 expansion phase of the trial, which will pre-screen subjects for EphA3 expression and assess the activity of KB004, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) when confirmatory safety and pharmacokinetic data is obtained from the Phase 1 trial.

Corporate Information

We were incorporated on March 15, 2000 in California and reincorporated as a Delaware corporation in September 2001. Our principal offices are located at 260 East Grand Avenue, South San Francisco, CA, 94080, and our telephone number is (650) 243-3100. We maintain a website on the Internet at www.kalobios.com. Our website, and the information contained therein, is not a part of this prospectus.

The Securities We May Offer

We may offer up to $100,000,000 of common stock, warrants and/or units in one or more offerings and in any combination. This prospectus provides you with a general description of the securities we may offer. A prospectus supplement, which we will provide each time we offer securities, will describe the specific amounts, prices and terms of these securities.

Common Stock

Each holder of our common stock is entitled to one vote for each share on all matters to be voted upon by the stockholders, and there are no cumulative rights. Subject to any preferential rights of any outstanding preferred stock, holders of our common stock are entitled to receive ratably the dividends, if any, as may be declared from time to time by the board of directors out of funds legally available therefor. If there is a liquidation, dissolution or winding up of our company, holders of our common stock would be entitled to share in our assets remaining after the payment of liabilities and any preferential rights of any outstanding preferred stock.

Warrants

We may issue warrants for the purchase of common stock. We may issue warrants independently or together with other securities.

Units

We may issue units comprised of one or more of the other classes of securities issued by us as described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit.

RISK FACTORS

An investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities will contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading “Risk Factors” in the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, all of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.

FORWARD-LOOKING STATEMENTS

This prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement includes forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements, and similar expressions and comparable terminology intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

•

our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;

•

our anticipated growth strategies;

•

our expectations regarding competition;

•

the anticipated trends and challenges in our business and the market in which we operate;

•

the timing and success of preclinical studies and clinical trials conducted by us and our development partners, including the timing of Sanofi’s initiation of a Phase 2b clinical trial of our KB001-A product candidate for ventilator associated pneumonia (VAP) caused by Pseudomonas aeruginosa (Pa) (Pa VAP), and our expectations as to the timing of enrollment and availability of clinical data;

•

the ability to obtain and maintain regulatory approval of our product candidates, and the labeling for any approved products;

•

the scope, progress, expansion, and costs of developing and commercializing our product candidates;

•

the size and growth of the potential markets for our product candidates and the ability to serve those markets;

•

the rate and degree of market acceptance of any of our product candidates;

•

our ability to establish and maintain development partnerships;

•

our ability to attract or retain key personnel;

•

our expectations regarding federal, state and foreign regulatory requirements;

•

regulatory developments in the United States and foreign countries; and

•

our ability to obtain and maintain intellectual property protection for our product candidates.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.

Any forward-looking statement made by us in this prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement speaks only as of the date on which it is made. Except as required by law, we assume no obligation to update these statements publicly, or to update the reasons actual results could differ materially from those anticipated in these statements, even if new information becomes available in the future.

Unless required by U.S. federal securities laws, we do not intend to update any of these forward-looking statements to reflect circumstances or events that occur after the statement is made.

You should read this prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

USE OF PROCEEDS

Unless otherwise indicated in the prospectus supplement, we will use the net proceeds from the sale of securities offered by this prospectus primarily to develop and advance our product candidates through clinical trials, as well as for working capital and general corporate purposes.

The amounts and timing of any expenditures will vary depending on: the type, number, costs, and results of the product candidate development programs which we are pursuing or may choose to pursue in the future; the scope, progress, expansion, costs, and results of our clinical trials; the amounts and timing of any contingent payments from Sanofi; competitive and technological developments; and the rate of growth, if any, of our business. Accordingly, unless otherwise indicated in the prospectus supplement, our management will have significant flexibility in applying the net proceeds of the offerings, and investors will be relying on the judgment of our management regarding the application of these net proceeds. Pending the uses described above, we intend to invest the net proceeds from this offering in short-term, interest-bearing, investment-grade securities.

DESCRIPTION OF CAPITAL STOCK

The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation and amended and restated bylaws, which have been filed with the SEC as exhibits to our registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.

Our authorized capital stock consists of 47,500,000 shares of common stock, par value $0.001 per share. As of August 30, 2013, there were 24,296,962 shares of common stock outstanding, held by 81 stockholders of record, although we believe that there may be a significantly larger number of beneficial owners of our common stock. We derived the number of stockholders by reviewing the listing of outstanding common stock recorded by our transfer agent as of August 30, 2013.

Common Stock

Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders and there are no cumulative rights. Holders of our common stock are entitled to receive ratably the dividends, if any, as may be declared from time to time by the board of directors out of funds legally available therefor. If there is a liquidation, dissolution or winding up of our company, holders of our common stock would be entitled to share in our assets remaining after the payment of liabilities. Holders of our common stock have no preemptive or conversion rights or other subscription rights, and there are no redemption or sinking fund provisions applicable to the common stock. The outstanding shares of common stock are fully paid and non-assessable.

Our common stock is listed on The NASDAQ Global Market under the symbol “KBIO.” The transfer agent and registrar for the common stock is Computershare Trust Company, N.A. The transfer agent’s address is 250 Royall Street, Canton, Massachusetts 02021 and its telephone number is (800) 662-7232.

Dividend

We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We expect to retain future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our common stock will be at the discretion of our board of directors and will depend upon, among other factors, our financial condition, operating results, current and anticipated cash needs, plans for expansion and other factors that our board of directors may deem relevant.

Anti-Takeover Provisions of Our Charter Documents

Some provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult to acquire our company by means of a tender offer, a proxy contest, or otherwise.

Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors.

Our amended and restated certificate of incorporation and amended and restated bylaws both provide that vacancies on our board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office, and directors so chosen shall hold office for a term expiring at the next annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified. Accordingly, the board of directors could prevent any stockholder from filling the new directorships with such stockholder’s own nominee.

Delaware Anti-Takeover Law

We are subject to Section 203 of the Delaware General Corporation Law which contains anti-takeover provisions. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date that the person became an interested stockholder, unless the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a business combination includes a merger, asset or stock sale or another transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns 15% or more of the corporation’s voting stock. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price fort the shares of common stock held by stockholders.

No Cumulative Voting

Under Delaware law, cumulative voting for the election of directors is not permitted unless a corporation’s certificate of incorporation authorizes cumulative voting. Our amended and restated certificate of incorporation does not provide for cumulative voting in the election of directors. Cumulative voting allows a minority stockholder to vote a portion or all of its shares for one or more candidates for seats on our board of directors. Without cumulative voting, a minority stockholder will not be able to gain as many seats on our board of directors based on the number of shares of our stock the stockholder holds as compared to the number of seats the stockholder would be able to gain if cumulative voting were permitted. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on our board of directors to influence our board’s decision regarding a takeover.

DESCRIPTION OF WARRANTS

General

We may issue warrants for the purchase of our common stock. Warrants may be issued independently or together with our common stock and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the warrants. The warrant agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. This summary of certain provisions of the warrants is not complete. For the terms of a particular series of warrants, you should refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series.

The prospectus supplement relating to a particular series of warrants to purchase our common stock will describe the terms of the warrants, including the following:

•

the title of the warrants;

•

the offering price for the warrants, if any;

•

the aggregate number of warrants;

•

the designation and terms of the common stock that may be purchased upon exercise of the warrants;

•

if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each security;

•

if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable;

•

the number of shares of common stock that may be purchased upon exercise of a warrant and the exercise price for the warrants;

•

the dates on which the right to exercise the warrants shall commence and expire;

•

if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;

•

the currency or currency units in which the offering price, if any, and the exercise price are payable;

•

if applicable, a discussion of material U.S. federal income tax considerations;

•

the antidilution provisions of the warrants, if any;

•

the redemption or call provisions, if any, applicable to the warrants;

•

any provisions with respect to the holder’s right to require us to repurchase the warrants upon a change in control or similar event; and

•

any additional terms of the warrants, including procedures, and limitations relating to the exchange, exercise and settlement of the warrants.

Holders of warrants will not be entitled:

•

to vote, consent or receive dividends;

•

to receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter; or

•

to exercise any rights as stockholders of KaloBios.

DESCRIPTION OF UNITS

We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent, if any, in the applicable prospectus supplement relating to a particular series of units. This summary of certain provisions of the units is not complete. For the terms of a particular series of units, you should refer to the prospectus supplement for that series of units and the unit agreement for that particular series. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus.

The prospectus supplement relating to a particular series of units will describe the terms of the units, including the following:

•

the title of the series of units;

•

identification and description of the separate constituent securities comprising the units;

•

the price or prices at which the units will be issued;

•

the date, if any, on and after which the constituent securities comprising the units will be separately transferable;

•

a discussion of certain United States federal income tax considerations applicable to the units; and

•

any other terms of the units and their constituent securities.

PLAN OF DISTRIBUTION

We may sell the securities offered through this prospectus (1) to or through underwriters or dealers, (2) directly to purchasers, including our affiliates, (3) through agents, or (4) through a combination of any these methods. The securities may be distributed at a fixed price or prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or negotiated prices. The prospectus supplement will include the following information:

•

the terms of the offering;

•

the names of any underwriters or agents;

•

the name or names of any managing underwriter or underwriters;

•

the purchase price of the securities;

•

the net proceeds from the sale of the securities;

•

any delayed delivery arrangements;

•

any underwriting discounts, commissions and other items constituting underwriters’ compensation;

•

any public offering price;

•

any discounts or concessions allowed or reallowed or paid to dealers; and

•

any commissions paid to agents.

Sale through underwriters or dealers

If underwriters are used in the sale, the underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all the offered securities if they purchase any of them. The underwriters may change from time to time any public offering price and any discounts or concessions allowed or reallowed or paid to dealers. The prospectus supplement will include the names of the principal underwriters the respective amount of securities underwritten, the nature of the obligation of the underwriters to take the securities and the nature of any material relationship between an underwriter and us.

If dealers are used in the sale of securities offered through this prospectus, we will sell the securities to them as principals. They may then resell those securities to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the dealers and the terms of the transaction.

Direct sales and sales through agents

We may sell the securities offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also be sold through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities and will describe any commissions payable to the agent by us. Unless otherwise indicated in the prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.

We may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.

Delayed delivery contracts

If the prospectus supplement indicates, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable prospectus supplement will describe the commission payable for solicitation of those contracts.

Market making, stabilization and other transactions

Unless the applicable prospectus supplement states otherwise, each series of offered securities will be a new issue and will have no established trading market. We may elect to list any series of offered securities on an exchange. Any underwriters that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time without notice. Therefore, we cannot assure you that the securities will have a liquid trading market.

Any underwriter may also engage in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Securities Exchange Act of 1934, as amended. Stabilizing transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions.

Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters may, if they commence these transactions, discontinue them at any time.

Derivative transactions and hedging

We, the underwriters or other agents may engage in derivative transactions involving the securities. These derivatives may consist of short sale transactions and other hedging activities. The underwriters or agents may acquire a long or short position in the securities, hold or resell securities acquired and purchase options or futures on the securities and other derivative instruments with returns linked to or related to changes in the price of the securities. In order to facilitate these derivative transactions, we may enter into security lending or repurchase agreements with the underwriters or agents. The underwriters or agents may effect the derivative transactions through sales of the securities to the public, including short sales, or by lending the securities in order to facilitate short sale transactions by others. The underwriters or agents may also use the securities purchased or borrowed from us or others (or, in the case of derivatives, securities received from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close out any related open borrowings of the securities.

Electronic auctions

We may also make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities directly to the public, with or without the involvement of agents, underwriters or dealers, utilizing the Internet or other forms of electronic bidding or ordering systems for the pricing and allocation of such securities, you should pay particular attention to the description of that system we will provide in a prospectus supplement.

Such electronic system may allow bidders to directly participate, through electronic access to an auction site, by submitting conditional offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which such securities are sold. These bidding or ordering systems may

present to each bidder, on a so-called “real-time” basis, relevant information to assist in making a bid, such as the clearing spread at which the offering would be sold, based on the bids submitted, and whether a bidder’s individual bids would be accepted, prorated or rejected.

Upon completion of such an electronic auction process, securities will be allocated based on prices bid, terms of bid or other factors. The final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole or in part on the results of the Internet or other electronic bidding process or auction.

General information

Agents, underwriters, and dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under the Securities Act.

LEGAL MATTERS

The validity of the securities offered by this prospectus will be passed upon by Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Redwood City, CA.

EXPERTS

The consolidated financial statements of KaloBios Pharmaceuticals, Inc. appearing in the KaloBios Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December 31, 2012 have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at http://www.sec.gov. You may also read and copy any document we file at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

We have filed with the SEC a registration statement under the Securities Act of 1933 relating to the offering of these securities. The registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement, at prescribed rates, from the SEC at the address listed above. The registration statement and the documents referred to below under “Information Incorporated by Reference” are also available on our Internet website, www.kalobios.com. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.

INFORMATION INCORPORATED BY REFERENCE

The SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose important information by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed “filed” pursuant to the General Instructions of Form 8-K):

•

our Annual Report on Form 10-K for the year ended December 31, 2012 filed on April 1, 2013;

•

our Quarterly Report on Form 10-Q for the quarterly period ended on March 31, 2013 filed on April 29, 2013;

•

our Quarterly Report on Form 10-Q for the quarterly period ended on June 30, 2013 filed on August 19, 2013;

•

All information in our proxy statement filed with the Securities and Exchange Commission on April 29, 2013 to the extent incorporated by reference in our Annual Report on Form 10-K for the year ended December 31, 2012;

•

Current Reports on Form 8-K (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed on January 10, 2013, January 15, 2013, February 1, 2013, June 24, 2013, August 6, 2013 and August 8, 2013; and

•

the description of our common stock contained in our Registration Statement on Form 8-A as filed with the SEC on January 30, 2013 pursuant to Section 12(b) of the Exchange Act.

We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement.

This prospectus may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by reference in this prospectus. You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.

We will provide to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, at no cost to the requester, a copy of any and all of the information that is incorporated by reference in this prospectus.

Requests for such documents should be directed to:

KaloBios Pharmaceuticals, Inc.

260 East Grand Avenue

South San Francisco, CA 94080

(650) 243-3100

You may also access the documents incorporated by reference in this prospectus through our website at www.kalobios.com. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part.

$100,000,000

LOGO

COMMON STOCK

WARRANTS

UNITS

PROSPECTUS

SUBJECT TO COMPLETION, DATED SEPTEMBER 3, 2013

PROSPECTUS

$50,000,000

LOGO

COMMON STOCK

In accordance with the terms of the At-the-Market Issuance Sales Agreement entered into with MLV & Co. LLC, or MLV, dated September 3, 2013, which we refer to as the sales agreement, we may offer and sell shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50,000,000 from time to time through MLV, acting as agent.

Our common stock is listed on The NASDAQ Global Market under the symbol “KBIO.” The last reported sale price of our common stock on August 30, 2013 was $5.57 per share.

Sales of our common stock, if any, under this prospectus will be made by any method permitted that is deemed an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by MLV and us. MLV will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

MLV will be entitled to compensation at a commission rate of 3% of the gross sales price per share sold. In connection with the sale of the common stock on our behalf, MLV may be deemed to be an “underwriter” within the meaning of the Securities Act of 1933, as amended, and the compensation of MLV may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to MLV with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended.

INVESTING IN THESE SECURITIES INVOLVES SIGNIFICANT RISKS. BEFORE BUYING SHARES OF OUR COMMON STOCK, YOU SHOULD CAREFULLY CONSIDER THE RISK FACTORS BEGINNING ON PAGE 4 OF THIS PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS AND ANY FREE WRITING PROSPECTUS THAT WE HAVE AUTHORIZED FOR USE IN CONNECTION WITH THIS OFFERING.

LOGO

The date of this prospectus is , 2013

TABLE OF CONTENTS


	Page
ABOUT THIS PROSPECTUS		1
PROSPECTUS SUMMARY		2
RISK FACTORS		4
FORWARD-LOOKING STATEMENTS		5
USE OF PROCEEDS		7
DILUTION		8
DIVIDEND POLICY		9
PLAN OF DISTRIBUTION		10
LEGAL MATTERS		11
EXPERTS		11
WHERE YOU CAN FIND ADDITIONAL INFORMATION		11
INFORMATION INCORPORATED BY REFERENCE		12

ABOUT THIS PROSPECTUS

This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus, together with the information incorporated by reference as described under the heading “Where You Can Find Additional Information” and “Information Incorporated by Reference.” These documents contain important information that you should consider when making your investment decision.

This prospectus describes the specific terms of the common stock we are offering and also adds to and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference in this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference into this prospectus—the statement in the document having the later date modifies or supersedes the earlier statement.

You should only rely on the information contained or incorporated by reference in this prospectus and any issuer free writing prospectus that we may authorize for use in connection with this offering. No person has been authorized to give any information or make any representations in connection with this offering other than those contained or incorporated by reference in this prospectus and any related issuer free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized by us. Neither this prospectus nor any related issuer free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits.

You should read the entire prospectus and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein or in any issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such issuer free writing prospectus. You should assume that the information appearing in this prospectus or any document incorporated by reference is accurate only as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects may have changed since that date.

PROSPECTUS SUMMARY

This summary description about us and our business highlights selected information contained elsewhere in this prospectus or incorporated in this prospectus by reference. This summary does not contain all of the information you should consider before investing in our common stock. You should carefully read this entire prospectus and any issuer free writing prospectus, including each of the documents incorporated herein or therein by reference, and the information referred to under the heading “Risk Factors” in this prospectus beginning on page 4, before making an investment decision. As used in this prospectus, “we,” “us,” “KaloBios” and “our” refer to KaloBios Pharmaceuticals, Inc., a Delaware corporation.

KaloBios Pharmaceuticals, Inc.

Overview

We currently have three monoclonal antibodies at the clinical development stage:

•

Our first antibody, KB003 (a Humaneered^®, recombinant, anti-granulocyte macrophage colony- stimulating factor (anti-GM-CSF) monoclonal antibody), is in a Phase 2 clinical trial in severe asthma patients inadequately controlled by corticosteroids. We plan to report data from this trial by early 2014. KB002, the chimeric precursor molecule to KB003, showed activity with a single dose in a Phase 1/2 clinical study in persistent asthma and in a Phase 1 clinical study in rheumatoid arthritis (RA).

•

Our third antibody, KB004 (a Humaneered^®, recombinant anti-EphA3 receptor tyrosine kinase monoclonal antibody), is in the dose escalation portion of a Phase 1 clinical trial in patients with hematologic malignancies. We plan to initiate the Phase 2 expansion phase of the trial, which will pre- screen subjects for EphA3 expression and assess the activity of KB004, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) when confirmatory safety and pharmacokinetic data is obtained from the Phase 1 trial.

Corporate Information

The Offering


Common stock offered by us pursuant to this prospectus supplement		Shares of our common stock having an aggregate offering price of up to $50,000,000.

Manner of offering		“At the market” offering that may be made from time to time on The NASDAQ Global Market or other market for our common stock in the U.S. through our agent, MLV. See the section entitled “Plan of Distribution” below.

Use of proceeds		We intend to use the net proceeds of this offering primarily to develop and advance our product candidates through clinical trials, as well as for working capital and general corporate purposes. See the section entitled “Use of Proceeds” below

Risk factors		See “Risk Factors” beginning on page 4 and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.

NASDAQ Global Market symbol		KBIO

RISK FACTORS

An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should carefully consider the risks and uncertainties described below, together with the information under the heading “Risk Factors” in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and our Quarterly Reports on Form 10-Q for the three-month periods ended March 31, 2013 and June 30, 2013, as updated or superseded by the risks and uncertainties described under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus, together with all of the other information contained or incorporated by reference in this prospectus and any issuer free writing prospectus that we may authorize for use in connection with this offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business prospects, financial condition or results of operations could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled “Forward-Looking Statements.”

Additional Risks Relating to this Offering

Our management team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return.

Our management will have broad discretion over the use of proceeds from this offering. The net proceeds from this offering will be used primarily to develop and advance our product candidates through clinical trials, as well as for working capital and general corporate purposes. However, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates.

You may experience future dilution as a result of future equity offerings.

Because the prices per share at which shares of our common stock are sold in this offering may be substantially higher than the book value per share of our common stock, you may suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering. The shares sold in this offering, if any, will be sold from time to time at various prices. After giving effect to the sale of our common stock in the maximum aggregate offering amount of $50,000,000 at an assumed offering price of $5.57 per share, the last reported sale price of our common stock on The NASDAQ Global Market on August 30, 2013, and after deducting estimated offering commissions payable by us, our net tangible book value as of June 30, 2013 would have been $97.3 million, or $2.93 per share of common stock. This represents an immediate increase in the net tangible book value of $0.90 per share to our existing stockholders and an immediate and substantial dilution in net tangible book value of $2.64 per share to new investors who purchase our common stock in the offering. See “Dilution” for a more detailed discussion of the dilution you may incur in connection with this offering.

FORWARD-LOOKING STATEMENTS

This prospectus and the information incorporated by reference in this prospectus include forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

•

our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;

•

our anticipated growth strategies;

•

our expectations regarding competition;

•

the anticipated trends and challenges in our business and the market in which we operate;

•

the ability to obtain and maintain regulatory approval of our product candidates, and the labeling for any approved products;

•

the scope, progress, expansion, and costs of developing and commercializing our product candidates;

•

the size and growth of the potential markets for our product candidates and the ability to serve those markets;

•

the rate and degree of market acceptance of any of our product candidates;

•

our ability to establish and maintain development partnerships;

•

our ability to attract or retain key personnel;

•

our expectations regarding federal, state and foreign regulatory requirements;

•

regulatory developments in the United States and foreign countries; and

•

our ability to obtain and maintain intellectual property protection for our product candidates.

Any forward-looking statement made by us in this prospectus and the information incorporated by reference in this prospectus speaks only as of the date on which it is made. Except as required by law, we assume no obligation to update these statements publicly, or to update the reasons actual results could differ materially from those anticipated in these statements, even if new information becomes available in the future.

Unless required by U.S. federal securities laws, we do not intend to update any of these forward-looking statements to reflect circumstances or events that occur after the statement is made.

You should read this prospectus and the information incorporated by reference in this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

USE OF PROCEEDS

The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with MLV as a source of financing.

We will use the net proceeds from the sale of our common stock offered by this prospectus primarily to develop and advance our product candidates through clinical trials, as well as for working capital and general corporate purposes.

The amounts and timing of any expenditures will vary depending on: the type, number, costs, and results of the product candidate development programs which we are pursuing or may choose to pursue in the future; the scope, progress, expansion, costs, and results of our clinical trials; the amounts and timing of any contingent payments from Sanofi; competitive and technological developments; and the rate of growth, if any, of our business. Accordingly, our management will have significant flexibility in applying the net proceeds of the offerings, and investors will be relying on the judgment of our management regarding the application of these net proceeds. Pending the uses described above, we intend to invest the net proceeds from this offering in short-term, interest-bearing, investment-grade securities.

DILUTION

If you invest in our common stock, your interest will be diluted to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book value of our common stock as of June 30, 2013 was approximately $49.1 million, or approximately $2.03 per share of common stock based upon 24,219,456 shares outstanding at that time. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares outstanding as of June 30, 2013.

After giving effect to the sale of our common stock in the aggregate amount of $50,000,000 at an assumed offering price of $5.57 per share, the last reported sale price of our common stock on The NASDAQ Global Market on August 30, 2013, and after deducting estimated offering commissions payable by us, our net tangible book value as of August 30, 2013 would have been $97.3 million, or $2.93 per share of common stock based on 33,196,117 shares of common stock outstanding on a pro forma basis at that time. This represents an immediate increase in net tangible book value of $0.90 per share to our existing stockholders and an immediate dilution in net tangible book value of $2.64 per share to new investors in this offering.

The following table illustrates this calculation on a per share basis as of June 30, 2013:


Offering price per share	$	5.57
Net tangible book value per share	$	2.03
Increase in net tangible book value per share attributable to the offering	$	0.90
Pro forma net tangible book value per share after giving effect to the offering	$	2.93
Dilution in net tangible book value per share to new investors	$	2.64

The foregoing table does not give effect to the exercise of any outstanding options or warrants. To the extent options and warrants are exercised, there may be further dilution to new investors.

The number of shares of our common stock to be outstanding immediately after this offering on a pro forma basis is based on 24,219,456 shares of our common stock outstanding as of June 30, 2013 and excludes:

•

88,545 shares issuable upon exercise of outstanding warrants as of June 30, 2013 with a weighted average exercise price of $9.04; and

•

1,720,637 shares issuable upon exercise of outstanding options as of June 30, 2013 with a weighted average exercise price of $3.22.

DIVIDEND POLICY

PLAN OF DISTRIBUTION

We have entered into an At-the-Market Issuance Sales Agreement, or, sales agreement with MLV to issue and sell up to $50,000,000 worth of our common stock from time to time under this prospectus. MLV will act as agent in the offering, subject to certain limitations, including the number of shares registered under the registration statement to which the offering relates.

The sales, if any, of shares made under the sales agreement will be made by any method that is deemed an “at the market” offering as defined in Rule 415 promulgated under the Securities Act, including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by MLV and us. We may instruct MLV not to sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or MLV may suspend the offering of common stock upon notice and subject to other conditions. As an agent, MLV will not engage in any transactions that stabilize the price of our common stock.

Each time we wish to issue and sell common stock under the sales agreement, we will notify MLV of the number of shares to be issued, the dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and other sales parameters as we deem appropriate. Once we have so instructed MLV, unless MLV declines to accept the terms of the notice, MLV has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of MLV under the sales agreement to sell our common stock is subject to a number of conditions that we must meet.

We will pay MLV commissions for its services in acting as agent in the sale of common stock. MLV will be entitled to a commission of up to 3% of the gross proceeds from the sale of common stock offered hereby. In addition, we have agreed to reimburse certain expenses of MLV in an amount not to exceed $25,000. We estimate that the total expenses for the offering, excluding compensation payable to MLV under the terms of the sales agreement, will be approximately $300,000.

Settlement for sales of common stock will occur on the third business day following the date on which any sales are made, or on some other date that is agreed upon by us and MLV in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

In connection with the sale of the common stock on our behalf, MLV may, and will with respect to sales effected in an “at the market” offering, be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of MLV may be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to MLV against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to reimburse MLV for certain other specified expenses.

The offering will terminate as permitted under the sales agreement.

MLV and its affiliates may in the future provide various investment banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, MLV will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus.

LEGAL MATTERS

The validity of the securities offered by this prospectus will be passed upon by Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Redwood City, CA. LeClairRyan, A Professional Corporation, New York, NY, is counsel for MLV in connection with this offering.

EXPERTS

WHERE YOU CAN FIND ADDITIONAL INFORMATION

INFORMATION INCORPORATED BY REFERENCE

The SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose important information by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus. We incorporate by reference the documents listed below that we have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed “filed” pursuant to the General Instructions of Form 8-K):

•

our Annual Report on Form 10-K for the year ended December 31, 2012 filed on April 1, 2013;

•

our Quarterly Report on Form 10-Q for the quarterly period ended on March 31, 2013 filed on April 29, 2013;

•

our Quarterly Report on Form 10-Q for the quarterly period ended on June 30, 2013 filed on August 19, 2013;

•

the description of our common stock contained in our Registration Statement on Form 8-A as filed with the SEC on January 30, 2013 pursuant to Section 12(b) of the Exchange Act.

Requests for such documents should be directed to:

KaloBios Pharmaceuticals, Inc.

260 East Grand Avenue

South San Francisco, CA 94080

(650) 243-3100

$50,000,000

LOGO

COMMON STOCK

PROSPECTUS

LOGO

The date of this prospectus is , 2013.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14.

Other Expenses of Issuance and Distribution

The following table sets forth the estimated costs and expenses (other than the actual registration fee), other than underwriting discounts and commissions, payable by the registrant in connection with the sale of the securities being registered.


Securities and Exchange Commission registration fee	$	13,640
Accounting fees and expenses	$	(1	)
Legal fees and expenses	$	(1	)
Printing and engraving	$	(1	)
Transfer agent fees and expenses	$	(1	)
Miscellaneous	$	(1	)
	$	(1	)
Total	$	(1	)

(1)	These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time.

Item 15.

Indemnification of Directors and Officers.

Section 145(a) of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no cause to believe his or her conduct was unlawful.

Section 145(b) of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if he or she acted under similar standards, except that no indemnification may be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the court in which such action or suit was brought shall determine that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to be indemnified for such expenses which the court shall deem proper.

Section 145 of the Delaware General Corporation Law further provides that: (i) to the extent that a former or present director or officer of a corporation has been successful in the defense of any action, suit or proceeding referred to in subsections (a) and (b) or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by him or her in connection therewith; (ii) indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and (iii) the corporation may purchase and maintain insurance on behalf of any present or former director, officer, employee or agent of the corporation or any person

II-1

who at the request of the corporation was serving in such capacity for another entity against any liability asserted against such person and incurred by him or her in any such capacity or arising out of his or her status as such, whether or not the corporation would have the power to indemnify him or her against such liabilities under Section 145.

In accordance with our amended and restated certificate of incorporation and our amended and restated bylaws, we have indemnification obligations to our officers and directors for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. We have also entered into indemnification agreements with our directors, executive officers, and key employees and intend to enter into indemnification agreements with any new directors and executive officers in the future.

We have purchased and intend to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

See also the undertakings set out in response to Item 17 herein.

Item 16.

Exhibits.

A list of exhibits filed herewith is contained in the exhibit index that immediately precedes such exhibits and is incorporated herein by reference.

Item 17.

Undertakings.

(a)	The undersigned registrant hereby undertakes:

(1)

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)

To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii)

To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(iii)

To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2)

That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3)

To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

II-2

(4)

That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(i)

If the registrant is relying on Rule 430B,

(A)

Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(B)

Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to the effective date; or

(ii)

If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5)

That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer and sell such securities to such purchaser:

(i)

Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii)

Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii)

The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

II-3

(iv)

Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b)

The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c)

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding), is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

(d)	The undersigned registrant hereby undertakes that:

(1)

For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(2)

For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(e)

The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the SEC under Section 305(b)(2) of the Trust Indenture Act.

II-4

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this 3^rd day of September, 2013.


KALOBIOS PHARMACEUTICALS, INC.

By:		/s/ David W. Pritchard
		David W. Pritchard President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David W. Pritchard and Jeffrey H. Cooper, and each of them acting individually, as his true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement on Form S-3 with all exhibits thereto and all documents in connection therewith, including a Registration Statement under Rule 462(b) of the Securities Act, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


Signature	Title	Date

/s/ David W. Pritchard David W. Pritchard	President, Chief Executive Officer and Director (Principal Executive Officer)	September 3, 2013

/s/ Jeffrey H. Cooper Jeffrey H. Cooper	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	September 3, 2013

/s/ James I. Healy, M.D., Ph.D. James I. Healy, M.D., Ph.D.	Director, Chairman of the Board	September 3, 2013

/s/ Denise Gilbert, Ph.D. Denise Gilbert, Ph.D.	Director	September 3, 2013

/s/ Dennis Henner, Ph.D. Dennis Henner, Ph.D.	Director	September 3, 2013

/s/ V. Bryan Lawlis, Jr., Ph.D. V. Bryan Lawlis, Jr., Ph.D.	Director	September 3, 2013

/s/ Ted W. Love, M.D. Ted W. Love, M.D.	Director	September 3, 2013

/s/ Gary Lyons Gary Lyons	Director	September 3, 2013

/s/ Raymond M. Withy, Ph.D. Raymond M. Withy, Ph.D.	Director	September 3, 2013

II-5

EXHIBIT INDEX


Exhibit Number		Description of Document
1.1*		Form of Underwriting Agreement.

1.2		Sales Agreement, dated September 3, 2013, by and between KaloBios Pharmaceuticals, Inc. and MLV & Co. LLC.

3.1(1)		Amended and Restated Certificate of Incorporation of the Registrant (Exhibit 3.2).

3.2(1)		Amended and Restated Bylaws of the Registrant (Exhibit 3.4).

4.1(1)		Specimen of Stock Certificate evidencing shares of Common Stock (Exhibit 4.1).

4.2(2)		Amended and Restated Investors’ Rights Agreement, dated May 2, 2012, by and among the Registrant and the other parties thereto (Exhibit 4.7).

4.3*		Form of Warrant.

4.4*		Form of Unit Agreement.

5.1		Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.

23.1		Consent of Independent Registered Public Accounting Firm.

23.2		Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).

24.1		Power of Attorney (see page II-5).

*	To be filed by amendment or as an exhibit to a report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and incorporated herein by reference.

(1)	Incorporated by reference to the exhibits to the Registrant’s Registration Statement on Form S-1 (File No. 333-184299) filed on January 15, 2013. The number given in parentheses indicates the corresponding exhibit number in such Form S-1.

(2)	Incorporated by reference to the exhibits to Amendment No. 3 to the Registrant’s Registration Statement on Form 10-12G (File No. 000-54735) filed on September 12, 2012. The number given in parentheses indicates the corresponding exhibit number in such Form 10-12G.

EX-1.2 2 d590927dex12.htm EX-1.2 EX-1.2

Exhibit 1.2

KALOBIOS PHARMACEUTICALS, INC.

Common Stock

(par value $0.001 per share)

At-the-Market Issuance Sales Agreement

September 3, 2013

MLV & Co. LLC

1251 Avenue of the Americas

41^st Floor

New York, New York 10020

Ladies and Gentlemen:

KaloBios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:

1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through MLV, acting as agent, shares (the “Placement Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), up to an aggregate offering price of $50,000,000; provided however, that in no event shall the Company issue or sell through MLV acting as agent, such number of Placement Shares that (a) exceeds the number of shares of Common Stock registered on the effective Registration Statement (as defined below) pursuant to which the offering is being made, or (b) exceeds the number of authorized but unissued shares of Common Stock (the lesser of (a) $50,000,000 and (b), the “Maximum Amount”). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 1 on the number of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that MLV shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares through MLV will be effected pursuant to the Registration Statement (as defined below), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue any Placement Shares.

The Company shall file, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (the “Securities Act”), with the Securities and Exchange Commission (the “Commission”), a registration statement on Form S-3, including one or more base prospectuses relating to certain securities, including the Placement Shares, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder. The Company will, if necessary, prepare a prospectus supplement to the prospectus included as part of such registration statement specifically relating to the Placement Shares (the “Prospectus Supplement”). The Company will furnish to MLV, for use by MLV, copies of the prospectus included as part of such registration statement, as supplemented, if at all, by the Prospectus Supplement, relating to the Placement Shares. Except where the context otherwise requires, such registration statement, including all documents filed as part thereof or incorporated

by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act, is herein called the “Registration Statement.” The prospectus relating to the Placement Shares, including all documents incorporated or deemed incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such base prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, is herein called the “Prospectus.” Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated or deemed incorporated by reference therein, and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein (the “Incorporated Documents”).

For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, “EDGAR”).

2. Placements. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a “Placement”), it will notify MLV by email notice (or other method mutually agreed to in writing by the parties hereto of the number of Placement Shares, the time period during which sales are requested to be made, any limitation on the number of Placement Shares that may be sold in any one day and any minimum price below which sales may not be made (a “Placement Notice”), the form of which is attached hereto as Schedule 1. The Placement Notice shall originate from any of the individuals from the Company set forth on Schedule 3 (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from MLV set forth on Schedule 3, as such Schedule 3 may be amended from time to time. Provided the Company is otherwise in compliance with the terms of this Agreement, the Placement Notice shall be effective immediately upon receipt by MLV unless and until (i) MLV declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of the Placement Shares thereunder has been sold, (iii) the Company suspends or terminates the Placement Notice or (iv) this Agreement has been terminated under the provisions of Section 13. The amount of compensation to be paid by the Company to MLV in connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in Schedule 2. It is expressly acknowledged and agreed that neither the Company nor MLV will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to MLV and MLV does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control.

3. Sale of Placement Shares by MLV.

a. Subject to the terms and conditions of this Agreement, for the period specified in a Placement Notice, MLV will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The NASDAQ Global Market (the “Exchange”), to sell the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. MLV will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable by the Company to MLV pursuant to Section 2 with respect to such sales, and the Net Proceeds (as defined below) payable by MLV to the Company, with an itemization of the deductions made by MLV (as set forth in Section 5(b)) from the gross proceeds that it receives from such sales. Subject to the terms of a Placement Notice, MLV shall sell Placement Shares only by methods deemed to be an “at-the-market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on the Exchange, on any other existing trading market for the Common Stock or to or through a market maker. Subject to the terms of a Placement Notice, MLV may also sell Placement Shares by any other method permitted by law, including but not limited to in privately negotiated transactions, only with the Company’s express prior written consent (which may be in the form of email correspondence). “Trading Day” means any day on which Common Stock is purchased and sold on the Exchange.

b. During the term of this Agreement, neither MLV nor any of its affiliates or subsidiaries shall engage either directly or indirectly in (i) any short sale of any security of the Company, (ii) any sale of any security of the Company that MLV does not own or any sale which is consummated by the delivery of a security of the Company borrowed by, or for the account of, MLV or (iii) any market making, bidding, purchasing, stabilization or other trading activity with regard to the Common Stock or related derivative securities, or attempting to induce another person to do any of the foregoing, if such activity would be prohibited under Regulation M or other anti-manipulation rules under the Securities Act. Neither MLV nor any of its affiliates or subsidiaries shall engage in any proprietary trading or trading for MLV’s (or its affiliates’ or subsidiaries’) own account.

4. Suspension of Sales. The Company or MLV may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on Schedule 3, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission or email correspondence to each of the individuals of the other party set forth on Schedule 3), suspend any sale of Placement Shares; provided, however, that such suspension shall not affect or impair any party’s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the parties agrees that no such notice under this Section 4 shall be effective against any other party unless it is made to one of the individuals named on Schedule 3 hereto, as such Schedule may be amended from time to time.

5. Sale and Delivery to MLV; Settlement.

a. Sale of Placement Shares. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, upon MLV’s acceptance of the terms of the Placement Notice, and unless the sale of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, MLV, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that MLV will be successful in selling Placement Shares, (ii) MLV will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by MLV to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Placement Shares as required under this Agreement and (iii) MLV shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by MLV and the Company, and only then to the extent permitted by law and the rules and regulations of the Exchange.

b. Settlement of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will occur on the third (3^rd) Trading Day (or such earlier day as is industry practice for regular-way trading) following the date on which such sales are made (each, a “Settlement Date”). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will be equal to the aggregate sales price received by MLV, after deduction for (i) MLV’s compensation for such sales payable by the Company pursuant to Section 2 hereof, and (ii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.

c. Delivery of Placement Shares. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Placement Shares being sold by crediting MLV’s or its designee’s account (provided MLV shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System (“DWAC”) or by such other means of delivery as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement Date, MLV will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the Settlement Date. MLV will be responsible for providing DWAC instructions or instructions for delivery by other means with respect to the transfer of Placement Shares being sold. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date, through no fault of MLV, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in Section 11(a) hereto, it will (i) hold MLV harmless against any loss, claim, damage, or reasonable, documented expense (including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent (if applicable) and (ii) pay to MLV (without duplication) any compensation to which it would otherwise have been entitled absent such default.

d. Limitations on Offering Size. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate number of Placement Shares sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount, (B) the amount available for offer and sale under the currently effective Registration Statement and (C) the amount authorized from time to time to be issued and sold under this Agreement by the Company’s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to MLV in writing. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Company’s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to MLV in writing. Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.

6. Representations and Warranties of the Company. Except as disclosed in the Registration Statement or Prospectus (including the Incorporated Documents), the Company represents and warrants to, and agrees with MLV that as of the date of this Agreement and as of each Applicable Time (as defined below), unless such representation, warranty or agreement specifies a different date or time:

a. Registration Statement and Prospectus. The Company and, assuming no act or omission on the part of MLV that would make such statement untrue, the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3 under the Securities Act. Prior to the time of the delivery of the first Placement Notice hereunder, the Registration Statement will be filed with the Commission and will be declared effective under the Securities Act. The Prospectus will name MLV as the agent in the section entitled “Plan of Distribution.” Following the Registration Statement being declared effective, no stop order of the Commission preventing or suspending the use of the Registration Statement will have been issued, and no proceedings for that purpose will have been initiated by the Commission. The Registration Statement and, assuming no act or omission on the part of MLV that would make such statement untrue, the offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with Rule 415. Any statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been or will be so described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments or supplements and all documents incorporated by reference therein that were filed with the Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to MLV and its counsel. The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering material in connection with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus and any Issuer Free Writing Prospectus (as defined below) to which MLV has consented, such consent not to be unreasonably withheld, conditioned or delayed. The Common Stock is currently listed on the Exchange under the

trading symbol “KBIO”. The Company has not, in the 12 months preceding the date hereof, received notice from the Exchange to the effect that the Company is not in compliance with the listing or maintenance requirements of the Exchange. The Company has no reason to believe that it will not in the foreseeable future continue to be in compliance in all material respects with all such listing and maintenance requirements applicable to the Company.

b. No Misstatement or Omission. The Registration Statement, when it became or becomes effective, and the Prospectus, and any amendment or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date, will conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement thereto, on the date thereof and at each Applicable Time (defined below), did not or will not include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The documents incorporated by reference in the Prospectus did not, and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or necessary to make the statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall not apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished to the Company by MLV specifically for use in the preparation thereof.

c. Conformity with Securities Act and Exchange Act. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or any amendment or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission under the Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or will conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.

d. Financial Information. The consolidated financial statements of the Company included or incorporated by reference in the Registration Statement and the Prospectus, together with the related notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders’ equity of the Company for the periods specified and have been prepared in compliance in all material respects with the requirements of the Securities Act and Exchange Act, as applicable, as in effect as of the time of filing and in conformity with generally accepted accounting principles in the United States as in effect as of the time of filing (“GAAP”) applied on a consistent basis (except for such adjustments to accounting standards and practices as are noted therein) during the periods involved (subject, in the case of unaudited statements, to normal recurring adjustments and to the extent they may exclude footnotes or may be condensed or summarized statements); the other financial and statistical data with respect to the Company and the Subsidiaries contained or incorporated by reference in the Registration Statement and

the Prospectus, are accurately and fairly presented and prepared on a basis consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or incorporated by reference as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent (including any off balance sheet obligations), not described in the Registration Statement (including the exhibits thereto and Incorporated Documents), and the Prospectus which are required to be described in the Registration Statement or Prospectus (including the exhibits thereto and Incorporated Documents); and all disclosures contained or incorporated by reference in the Registration Statement and the Prospectus, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable;

e. Conformity with EDGAR Filing. The Prospectus delivered to MLV for use in connection with the sale of the Placement Shares pursuant to this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing via EDGAR, except to the extent permitted by Regulation S-T.

f. Organization. The Company and any subsidiary that is a significant subsidiary (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the Commission) (each, a “Subsidiary”, collectively, the “Subsidiaries”), are, and as of each Settlement Date will be, duly organized, validly existing as a corporation and in good standing under the laws of their respective jurisdictions of organization. The Company and the Subsidiaries are, and will be, duly licensed or qualified as a foreign corporation for transaction of business and in good standing under the laws of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such license or qualification, and have all corporate power and authority necessary to own or hold their respective properties and to conduct their respective businesses as described in the Registration Statement and the Prospectus (including the exhibits thereto and Incorporated Documents), except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have or reasonably be expected to have a material adverse effect on the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders’ equity or results of operations of the Company and the Subsidiaries taken as a whole, or prevent the consummation of the transactions contemplated hereby (a “Material Adverse Effect”).

g. Subsidiaries. As of the date hereof, the Company’s only Subsidiaries are set forth on Schedule 6(g). The Company owns directly or indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and similar rights.

h. No Violation or Default. Neither the Company nor any Subsidiary is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any

indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound or to which any of the property or assets of the Company or any Subsidiary is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company’s knowledge, no other party under any material contract or other agreement to which it or any Subsidiary is a party is in default in any respect thereunder where such default would reasonably be expected to have a Material Adverse Effect.

i. No Material Adverse Effect. Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement and Prospectus, there has not been (i) any Material Adverse Effect, (ii) other than the transactions contemplated by this agreement, any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or the Subsidiaries, which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock (other than (A) the grant of additional options or other equity awards under the Company’s existing stock option plans, (B) changes in the number of outstanding Common Stock of the Company due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof, (C) as a result of the issuance of Placement Shares, (D) any repurchases of capital stock of the Company, (E) as described in a proxy statement filed on Schedule 14A or a Registration Statement on Form S-4, or (F) otherwise publicly announced) or outstanding long-term indebtedness of the Company or the Subsidiaries or (v) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company or any Subsidiary, other than in each case above (A) in the ordinary course of business, (B) as otherwise disclosed in the Registration Statement or Prospectus or (C) where such matter, item, change, or development would not make the statements in the Registration Statement or the Prospectus contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

j. Capitalization. The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and non-assessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration Statement and the Prospectus as of the dates referred to therein (other than (i) the grant of additional options or other equity awards under the Company’s existing stock option plans, (ii) changes in the number of outstanding Common Stock of the Company due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof, (iii) as a result of the issuance of Placement Shares, or (iv) any repurchases of capital stock of the Company) and such authorized capital stock conforms in all material respects to the description thereof set forth in the Registration Statement and the Prospectus. The description of the Common Stock in the Registration Statement and the Prospectus is complete and accurate in all material respects. As of the date referred to therein, the Company did not have outstanding

any options to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or other securities.

k. S-3 Eligibility. (i) At the time of filing the Registration Statement and (ii) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus), the Company met the then applicable requirements for use of Form S-3 under the Securities Act, including compliance with General Instruction I.B.1 of Form S-3.

l. Authorization; Enforceability. The Company has corporate, power and authority to enter into this Agreement and perform the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a valid and binding agreement of the Company enforceable against the Company in accordance with its terms, except to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general equitable principles and (ii) the indemnification and contribution provisions of Section 11 hereof may be limited by federal or state securities laws and public policy considerations in respect thereof.

m. Authorization of Placement Shares. The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors of the Company or a duly authorized committee thereof, or a duly authorized executive officer, against payment therefor as provided herein, will be duly and validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance, security interest or other claim (other than any pledge, lien, encumbrance, security interest or other claim arising from an act or omission of MLV or a purchaser), including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when issued, will conform in all material respects to the description thereof set forth in or incorporated into the Prospectus.

n. No Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or any governmental or regulatory authority having jurisdiction over the Company is required for the execution, delivery and performance by the Company of this Agreement, and the issuance and sale by the Company of the Placement Shares as contemplated hereby, except for the registration of the Placement Shares under the Securities Act, which shall occur prior to the time of the delivery of the first Placement Notice hereunder, and such consents, approvals, authorizations, orders and registrations or qualifications as may be required under applicable state securities laws or by the by-laws and rules of the Financial Industry Regulatory Authority (“FINRA”) or the Exchange, in connection with the sale of the Placement Shares by MLV.

o. No Preferential Rights. (i) No person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act (each, a “Person”), has the right, contractual or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other capital stock or other securities of the Company (other than upon the exercise of options or warrants to purchase Common Stock or upon the exercise of options

that may be granted from time to time under the Company’s stock option plans), (ii) no Person has any preemptive rights, rights of first refusal, or any other rights (whether pursuant to a “poison pill” provision or otherwise) to purchase any Common Stock or shares of any other capital stock or other securities of the Company from the Company which have not been duly waived with respect to the offering contemplated hereby, (iii) except as may be disclosed to MLV in writing, no Person has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Common Stock, and (iv) no Person has the right, contractual or otherwise, to require the Company to register under the Securities Act any Common Stock or shares of any other capital stock or other securities of the Company, or to include any such shares or other securities in the Registration Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated thereby or otherwise, except for such rights as have been waived on or prior to the date hereof.

p. Independent Public Accountant. Ernst & Young LLP (the “Accountant”), whose report on the consolidated financial statements of the Company is filed with the Commission as part of the Company’s most recent Annual Report on Form 10-K filed with the Commission and incorporated into the Registration Statement, are and, during the periods covered by their report, were independent public accountants within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States). To the Company’s knowledge, the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) with respect to the Company.

q. Enforceability of Agreements. All agreements between the Company and third parties expressly referenced in the Prospectus, other than such agreements that have expired by their terms or whose termination is disclosed in documents filed by the Company on EDGAR, are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited by federal or state securities laws or public policy considerations in respect thereof, and except for any unenforceability that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

r. No Litigation. There are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company’s knowledge, any legal, governmental or regulatory investigations, to which the Company or a Subsidiary is a party or to which any property of the Company or any Subsidiary is the subject that, individually or in the aggregate, if determined adversely to the Company or any Subsidiary, would reasonably be expected to have a Material Adverse Effect or materially and adversely affect the ability of the Company to perform its obligations under this Agreement; to the Company’s knowledge, no such actions, suits or proceedings are threatened by any governmental or regulatory authority or threatened by others that, individually or in the aggregate, if determined adversely to the Company or any Subsidiary, would reasonably be expected to have a Material Adverse Effect; and there are no current or pending legal, governmental or regulatory actions, suits or proceedings, or, to the Company’s knowledge, investigations, that are required under the Securities Act to be described in the Prospectus that are not described in the Prospectus including any Incorporated Document.

s. Licenses and Permits. The Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents, orders, approvals, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement and the Prospectus (the “Permits”), except where the failure to possess, obtain or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary have received written notice of any proceeding relating to revocation or modification of any such Permit or has any reason to believe that such Permit will not be renewed in the ordinary course, except where the failure to obtain any such renewal would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

t. No Material Defaults. Neither the Company nor any Subsidiary has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of its last Annual Report on Form 10-K, indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred stock or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.

u. Certain Market Activities. Neither the Company, nor any Subsidiary, nor, to the Company’s knowledge, any of their respective directors, officers or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Placement Shares.

v. Broker/Dealer Relationships. Neither the Company nor any Subsidiary or any related entities (i) is required to register as a “broker” or “dealer” in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls or is a “person associated with a member” or “associated person of a member” (within the meaning set forth in the FINRA Manual).

w. No Reliance. The Company has not relied upon MLV or legal counsel for MLV for any legal, tax or accounting advice in connection with the offering and sale of the Placement Shares.

x. Taxes. The Company and the Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good faith, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect. Except as otherwise disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined adversely to

the Company or any Subsidiary which has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been asserted or threatened against it which would have a Material Adverse Effect.

y. Title to Real and Personal Property. The Company and the Subsidiaries have good and valid title in fee simple to all items of real property and good and marketable title to all personal property (excluding Intellectual Property, which is addressed below) described in the Registration Statement or Prospectus as being owned by them that are material to the businesses of the Company or such Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries or (ii) would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Any real property described in the Registration Statement or Prospectus as being leased by the Company and the Subsidiaries is held by them under valid, existing and enforceable leases, except those that (A) do not materially interfere with the use made or proposed to be made of such property by the Company or the Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect.

z. Intellectual Property. To the Company’s knowledge, the Company and the Subsidiaries own or possess adequate enforceable rights to use all patents, patent applications, trademarks (both registered and unregistered), service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) (collectively, the “Intellectual Property”), necessary for the conduct of their respective businesses as conducted as of the date hereof, except to the extent that the failure to own or possess adequate rights to use such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; except as may be disclosed in writing to MLV, the Company and the Subsidiaries have not received any written notice of any claim of infringement or conflict which asserted Intellectual Property rights of others, which infringement or conflict, if the subject of an unfavorable decision, would reasonably be expected to result in a Material Adverse Effect; there are no pending, or to the Company’s knowledge, threatened judicial proceedings or interference proceedings against the Company or its Subsidiaries challenging the Company’s or any of its Subsidiary’s rights in or to or the validity of the scope of any of the Company’s or any Subsidiary’s patents, patent applications or proprietary information, except for such proceedings that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; to the Company’s knowledge, no other entity or individual has any right or claim in any of the Company’s or any of its Subsidiary’s patents, patent applications or any patent to be issued therefrom by virtue of any contract, license or other agreement entered into between such entity or individual and the Company or any Subsidiary or by any non-contractual obligation, other than by written licenses granted by the Company or any Subsidiary, except for such right or claim that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; the Company and the Subsidiaries have not received any written notice of any claim challenging the rights of the Company or its Subsidiaries in or to any Intellectual Property owned, licensed or optioned by the Company or any Subsidiary which claim, if the subject of an unfavorable decision would reasonably be expected to result in a Material Adverse Effect.

aa. Environmental Laws. The Company and the Subsidiaries (i) are in compliance in all material respects with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (ii) have received and are in compliance in all material respects with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses as described in the Registration Statement and the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

bb. Disclosure Controls. The Company maintains systems of internal accounting controls designed to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company is not aware of any material weaknesses in its internal control over financial reporting (other than as set forth in the Registration Statement or the Prospectus). Since the date of the latest audited financial statements of the Company included in the Prospectus, there has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting (other than as set forth in the Registration Statement or the Prospectus). The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company and the Subsidiaries is made known to the certifying officers by others within those entities, particularly during the period in which the Company’s Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K for the fiscal year most recently ended (such date, the “Evaluation Date”). The Company presented in its Form 10-K for the fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the most recent Evaluation Date. Since the most recent Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is defined in Item 307(b) of Regulation S-K under the Securities Act) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal controls. To the knowledge of the Company, other than as set forth in the Registration Statement or Prospectus, including the Incorporated Documents, the Company’s “internal controls over financial reporting” and “disclosure controls and procedures” are effective.

cc. Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s directors or officers, in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements and other documents required to be filed by it or furnished by it to the Commission during the past 12 months. For purposes of the preceding sentence, “principal executive officer” and “principal financial officer” shall have the meanings given to such terms in the Exchange Act Rules 13a-15 and 15d-15.

dd. Finder’s Fees. Neither the Company nor any Subsidiary has incurred any liability for any finder’s fees, brokerage commissions or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to MLV pursuant to this Agreement.

ee. Labor Disputes. No labor disturbance by or dispute with employees of the Company or any Subsidiary exists or, to the knowledge of the Company, is threatened which would reasonably be expected to result in a Material Adverse Effect.

ff. Investment Company Act. Neither the Company nor any Subsidiary is or, after giving effect to the offering and sale of the Placement Shares, will be an “investment company” or an entity “controlled” by an “investment company,” as such terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”).

gg. Operations. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or the Subsidiaries are subject, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental agency having jurisdiction over the Company, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

hh. Off-Balance Sheet Arrangements. There are no transactions, arrangements and other relationships between and/or among the Company, and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity (each, an “Off Balance Sheet Transaction”) that would reasonably be expected to affect materially the Company’s liquidity or the availability of or requirements for its capital resources, including those Off Balance Sheet Transactions described in the Commission’s Statement about Management’s Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Registration Statement or the Prospectus which have not been described as required.

ii. Underwriter Agreements. The Company is not a party to any agreement with an agent or underwriter for any other “at-the-market” or continuous equity transaction; provided, however, that nothing in this Agreement shall prohibit the Company from entering into a committed equity financing or similar transaction.

jj. ERISA. To the knowledge of the Company, (i) each material employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), that is maintained, administered or contributed to by the Company or any of its affiliates for employees or former employees of the Company and the Subsidiaries has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the “Code”); (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and (iii) for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no “accumulated funding deficiency” as defined in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) equals or exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions other than, in the case of (i), (ii) and (iii) above, as would not reasonably be expected to have a Material Adverse Effect.

kk. Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) (a “Forward-Looking Statement”) contained in the Registration Statement and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

ll. Margin Rules. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System.

mm. Insurance. The Company and the Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company and the Subsidiaries reasonably believe are adequate for their business and as is customary for companies of similar size engaged in similar businesses in similar industries.

nn. No Improper Practices. (i) Neither the Company nor, to the Company’s knowledge, the Subsidiaries, nor to the Company’s knowledge, any of their respective executive officers has, in the past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in violation of law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any law or of the character required to be disclosed in the Prospectus; (ii) to the Company’s knowledge, no relationship, direct or indirect, exists between or among the Company or, to the Company’s knowledge, the Subsidiaries or any affiliate of any of them, on the one hand, and the

directors, officers and stockholders of the Company or, to the Company’s knowledge, the Subsidiaries, on the other hand, that is required by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described; (iii) to the Company’s knowledge, no relationship, direct or indirect, exists between or among the Company or the Subsidiaries or any affiliate of them, on the one hand, and the directors, officers, stockholders or directors of the Company or, to the Company’s knowledge, the Subsidiaries, on the other hand, that is required by the rules of FINRA to be described in the Registration Statement and the Prospectus that is not so described; (iv) there are no material outstanding loans or advances or material guarantees of indebtedness by the Company or, to the Company’s knowledge, the Subsidiaries to or for the benefit of any of their respective officers or directors or any of the members of the families of any of them; and (v) to the Company’s knowledge, the Company has not offered, or caused any placement agent to offer, Common Stock to any person with the intent to influence unlawfully (A) a customer or supplier of the Company or the Subsidiaries to alter the customer’s or supplier’s level or type of business with the Company or the Subsidiaries or (B) a trade journalist or publication to write or publish favorable information about the Company or the Subsidiaries or any of their respective products or services, and, (vi) neither the Company nor the Subsidiaries nor, to the Company’s knowledge, any employee or agent of the Company or the Subsidiaries has made any payment of funds of the Company or the Subsidiaries or received or retained any funds in violation of any law, rule or regulation (including, without limitation, the Foreign Corrupt Practices Act of 1977), which payment, receipt or retention of funds is of a character required to be disclosed in the Registration Statement or the Prospectus.

oo. Status Under the Securities Act. The Company was not and is not an ineligible issuer as defined in Rule 405 at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.

pp. No Misstatement or Omission in an Issuer Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date and as of each Applicable Time (as defined in Section 25 below), did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by MLV specifically for use therein.

qq. No Conflicts. Neither the execution of this Agreement by the Company, nor the issuance, offering or sale of the Placement Shares, nor the consummation by the Company of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company is a party or to which any of the property or assets of the Company is subject, except (i) such conflicts, breaches, defaults, liens charges or encumbrances as may have been waived and (ii) such conflicts, breaches and defaults that would not reasonably be expected to have a Material Adverse Effect; nor will such action result

(x) in any violation of the provisions of the certificate of incorporation or bylaws of the Company, or (y) in any material violation of the provisions of any statute or any order, rule or regulation applicable to the Company or of any court or of any federal, state or other regulatory authority or other government body having jurisdiction over the Company, except where such violation would not reasonably be expected to have a Material Adverse Effect.

rr. Compliance with Applicable Laws. The Company and the Subsidiaries: (A) are and at all times have been in material compliance with all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company or the Subsidiaries (“Applicable Laws”), (b) have not received any Form 483 from the FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European Medicines Agency (the “EMA”), or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would, individually or in the aggregate, result in a Material Adverse Effect; (C) possess all material Authorizations and such Authorizations are valid and in full force and effect and neither the Company nor the Subsidiaries is in material violation of any term of any such Authorizations; (D) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, the EMA, or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any Company product, operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA, the EMA, or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding against the Company; (E) have not received notice that the FDA, EMA, or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA, EMA, or any other federal, state, local or foreign governmental or regulatory authority is considering such action; and (F) have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations except where the failure to file such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments would not result in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).

ss. Clinical Studies. All animal and other preclinical studies and clinical trials conducted by the Company or, to the Company’s knowledge, on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials

contained in the Registration Statement and the Prospectus are accurate in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

tt. Compliance Program. The Company has taken such steps as the Company believes are reasonable and appropriate to comply in all material respects with applicable regulatory guidelines (including, without limitation, those administered by the FDA, the EMA, and any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA or EMA); except where such noncompliance would not reasonably be expected to have a Material Adverse Effect.

uu. OFAC.

(i) The Company represents that, neither the Company nor any Subsidiary (collectively, the “Entity”) or, to the Company’s knowledge, any director, officer, employee, agent, affiliate or representative of the Entity, is a government, individual, or entity (in this paragraph (ss), “Person”) that is, or is owned or controlled by a Person that is:

(a) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council (“UNSC”), the European Union (“EU”), Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority (collectively, “Sanctions”), nor

(b) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran, North Korea, Sudan and Syria).

(ii) The Entity represents and covenants that it will not, directly or indirectly, knowingly use the proceeds of the offering, or knowingly lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:

(a) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or

(b) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).

(iii) The Entity represents and covenants that, except as detailed in the Prospectus, for the past 5 years, it has not knowingly engaged in, is not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

vv. Stock Transfer Taxes. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to be paid by the Company in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with by the Company in all material respects.

Any certificate signed by an officer of the Company and delivered to MLV or to counsel for MLV pursuant to or in connection with this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to MLV as to the matters set forth therein.

7. Covenants of the Company. The Company covenants and agrees with MLV that:

a. Registration Statement Amendments. After the date of this Agreement and during any period in which a prospectus relating to any Placement Shares is required to be delivered by MLV under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act) (the “Prospectus Delivery Period”) (i) the Company will notify MLV promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference or amendments not related to any Placement, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus, other than documents incorporated by reference, has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus related to the Placement or for additional information related to the Placement, (ii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus (except for documents incorporated by reference) unless a copy thereof has been submitted to MLV within two Business Days before the filing and MLV has not reasonably and in good faith objected thereto within the two Business Day period (provided, however, that (A) the failure of MLV to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect MLV’s right to rely on the representations and warranties made by the Company in this Agreement and (B) the Company has no obligation to provide MLV any advance copy of such filing or to provide MLV an opportunity to object to such filing if the filing does not name MLV or does not relate to the transaction herein provided; and provided, further, that the only remedy MLV shall have with respect to the failure by the Company to provide MLV with such copy shall be to cease making sales under this Agreement) and the Company will furnish to MLV at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with the Commission as required pursuant to the Exchange Act, within the time period

prescribed (the determination to file or not file any amendment or supplement with the Commission under this Section 7(a), based on the Company’s reasonable opinion or reasonable objections, shall be made exclusively by the Company).

b. Notice of Commission Stop Orders. The Company will advise MLV, promptly after it receives notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will advise MLV promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares or for additional information related to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.

c. Delivery of Prospectus; Subsequent Changes. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to comply in all material respects with all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant to Rule 430A under the Securities Act, it will use its commercially reasonable efforts to comply with the provisions of and make all requisite filings with the Commission pursuant to said Rule 430A and to notify MLV promptly of all such filings. If during the Prospectus Delivery Period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such Prospectus Delivery Period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify MLV to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance; provided, however, that the Company may delay the filing of any amendment or supplement, if in the judgment of the Company, it is in the best interest of the Company.

d. Listing of Placement Shares. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on the Exchange and to qualify the Placement Shares for sale under the securities laws of such jurisdictions in the United States as MLV reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Placement Shares; provided, however, that the Company shall not be required in connection therewith to qualify as a foreign corporation or dealer in securities or file a general consent to service of process in any jurisdiction.

e. Delivery of Registration Statement and Prospectus. The Company will furnish to MLV and its counsel (at the reasonable expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus Delivery Period (including all documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such quantities as MLV may from time to time reasonably request and, at MLV’s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus) to MLV to the extent such document is available on EDGAR.

f. Earnings Statement. The Company will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.

g. Use of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”

h. Notice of Other Sales. Without the prior written consent of MLV, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common Stock during the period beginning on the date on which any Placement Notice is delivered to MLV hereunder and ending on the third (3rd) Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other “at-the-market” or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common Stock prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with the Company’s issuance or sale of (i) Common Stock, options to purchase or other equity awards for Common Stock or Common Stock issuable upon the exercise of options or other equity awards, pursuant to any employee or director stock option or benefits plan, stock ownership plan or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented; (ii) Common Stock issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise in writing to MLV, and (iii) Common Stock, or securities convertible into or exercisable for Common Stock, offered and sold in a privately negotiated transaction to vendors, customers, strategic partners or potential strategic partners or other investors conducted in a manner so as not to be integrated with the offering of Common Stock hereby.

i. Change of Circumstances. The Company will, at any time during the pendency of a Placement Notice advise MLV promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any opinion, certificate, letter or other document required to be provided to MLV pursuant to this Agreement.

j. Due Diligence Cooperation. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted by MLV or its representatives in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during regular business hours and at the Company’s principal offices or such other location mutually agreed by the parties hereto, as MLV may reasonably request.

k. Required Filings Relating to Placement of Placement Shares. The Company agrees that on such dates as the Securities Act shall require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act (the date of each and every filing under Rule 424(b), a “Filing Date”), which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold through MLV, the Net Proceeds to the Company and the compensation payable by the Company to MLV with respect to such Placement Shares or, if any such prospectus supplement is not filed pursuant to Rule 424(b), otherwise include such information in the Company’s Exchange Act filings on such date as shall be required, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market.

l. Representation Dates; Certificate. Within five (5) days of each time during the term of this Agreement that the Company:

(i) amends or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating to the Placement Shares;

(ii) files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A that contains amended or restated financial statements);

(iii) files its quarterly reports on Form 10-Q under the Exchange Act; or

(iv) files a current report on Form 8-K containing amended financial information (other than information “furnished” pursuant to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange Act;

(Each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date.”)

the Company shall furnish MLV (but in the case of clause (iv) above only if MLV reasonably determines that the information contained in such Form 8-K is material) with a certificate, in the form attached hereto as Exhibit 7(1). The requirement to provide a certificate under this Section 7(1) shall be waived for any Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date on which the Company files its annual report on Form 10-K. Notwithstanding the foregoing, (i) upon the delivery of the first Placement Notice hereunder and (ii) if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on such waiver and did not provide MLV with a certificate under this Section 7(1), then before MLV sells any Placement Shares, the Company shall provide MLV with a certificate, in the form attached hereto as Exhibit 7(1), dated the date of the Placement Notice.

m. Legal Opinion. On or prior to the date of the first Placement Notice given hereunder the Company shall cause to be furnished to MLV a written opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (“Company Counsel”), or other counsel reasonably satisfactory to MLV, covering opinions and statements in form and substance reasonably satisfactory to MLV. Thereafter, within five (5) Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit 7(l) for which no waiver is applicable, and not more than once per calendar quarter, the Company shall cause to be furnished to MLV a written letter of Company Counsel or other counsel reasonably satisfactory to MLV, in form and substance reasonably satisfactory to MLV; provided that, the Company shall not be required to furnish any such letter if the Company does not intend to deliver a Placement Notice in such calendar quarter until such time as the Company delivers its next Placement Notice.

n. Comfort Letter. On or prior to the date of the first Placement Notice given hereunder and within five (5) Trading Days after each subsequent Representation Date, other than pursuant to Section 7(l)(iii), with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit 7(l) for which no waiver is applicable, the Company shall cause its independent accountants to furnish MLV letters, in form and substance reasonably satisfactory to MLV (the “Comfort Letters”), dated the date the Comfort Letter is delivered, (i) confirming that they are an independent public accounting firm within the meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants’ “comfort letters” to underwriters in connection with registered public offerings (the first such letter, the “Initial Comfort Letter”) and (iii) updating the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.

o. Market Activities. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than MLV.

p. Investment Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor the Subsidiaries will be or become, at any time prior to the termination of this Agreement, an “investment company,” as such term is defined in the Investment Company Act.

q. No Offer to Sell. Other than an Issuer Free Writing Prospectus approved in advance by the Company and MLV in its capacity as agent hereunder pursuant to Section 23, neither MLV nor the Company (including its agents and representatives, other than MLV in their capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.

r. [Reserved]

8. Representations and Covenants of MLV. MLV represents and warrants that it is duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except such states in which MLV is exempt from registration or such registration is not otherwise required. MLV shall continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except such states in which MLV is exempt from registration or such registration is not otherwise required, during the term of this Agreement. MLV shall comply with all applicable law and regulations, including but not limited to Regulation M, in connection with the transactions contemplated by this Agreement, including the issuance and sale through MLV of the Placement Shares.

9. Payment of Expenses. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, filing, including any fees required by the Commission, and printing of the Registration Statement (including financial statements and exhibits) as originally filed and of each amendment and supplement thereto and each Free Writing Prospectus, in such number as MLV shall deem reasonably necessary, (ii) the printing and delivery to MLV of this Agreement and such other documents as may be reasonably required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii) the preparation, issuance and delivery of the certificates, if any, for the Placement Shares to MLV, including any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable upon the sale, issuance or delivery of the Placement Shares to MLV, (iv) the fees and disbursements of the counsel, accountants and other advisors to the Company, (v) the reasonable fees and disbursements of counsel to MLV up to a maximum of $25,000; (vi) the fees and expenses of the transfer agent and registrar for the Common Stock, (vii) the filing fees incident to any review by FINRA of the terms of the sale of the Placement Shares, and (viii) the fees and expenses incurred in connection with the listing of the Placement Shares on the Exchange.

10. Conditions to MLV’s Obligations. The obligations of MLV hereunder with respect to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the

Company of its obligations hereunder, to the completion by MLV of a due diligence review of the Company that is satisfactory to it in its reasonable judgment, and to the continuing satisfaction (or waiver by MLV in its sole discretion) of the following additional conditions:

a. Registration Statement Effective. The Registration Statement shall have become effective and shall be available for the sale of all Placement Shares contemplated to be issued by any Placement Notice.

b. No Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus which have not, as of the time of such Placement, been so made; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that requires the making of any changes in the Registration Statement or the Prospectus so that, in the case of the Registration Statement, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, which changes shall not, as of the time of such Placement, have been so made.

c. No Misstatement or Material Omission. MLV shall not have advised the Company that the Registration Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the reasonable opinion of MLV is material, or omits to state a fact that in the reasonable opinion of MLV is material and is required to be stated therein or is necessary to make the statements therein not misleading.

d. Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall not have been any material adverse change in the authorized capital stock of the Company or any Material Adverse Effect, or any development that would reasonably be expected to cause a Material Adverse Effect, that in each case, is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus

e. Legal Opinion. MLV shall have received the opinions and statements of Company Counsel required to be delivered pursuant to Section 7(m) on or before the date on which such delivery of such opinions are required pursuant to Section 7(m).

f. Comfort Letter. MLV shall have received the Comfort Letter required to be delivered pursuant to Section 7(n) on or before the date on which such delivery of such letter is required pursuant to Section 7(n).

g. Representation Certificate. MLV shall have received the certificate required to be delivered pursuant to Section 7(1) on or before the date on which delivery of such certificate is required pursuant to Section 7(1).

h. No Suspension. Trading in the Common Stock shall not have been suspended on the Exchange and the Common Stock shall not have been delisted from the Exchange.

i. [Reserved]

j. Securities Act Filings Made. All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424.

k. Approval for Listing. The Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to, the issuance of any Placement Notice.

l. No Termination Event. There shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a).

11. Indemnification and Contribution.

(a) Company Indemnification. The Company agrees to indemnify and hold harmless MLV, its partners, members, directors, officers, employees and agents and each person, if any, who controls MLV within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:

(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

(ii) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section 11(d) below) any such settlement is effected with the written consent of the Company, which consent shall not unreasonably be delayed or withheld; and

(iii) against any and all expense whatsoever, as incurred (including the reasonable documented fees and disbursements of counsel), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above,

provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written information furnished to the Company by MLV expressly for use in the Registration Statement (or any amendment thereto), or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto).

(b) MLV Indemnification. MLV agrees to indemnify and hold harmless the Company and its directors and each officer of the Company who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 11(a), as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto) or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating to MLV and furnished to the Company in writing by MLV expressly for use therein.

(c) Procedure. Any party that proposes to assert the right to be indemnified under this Section 11 will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section 11, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under this Section 11 and (ii) any liability that it may have to any indemnified party under the foregoing provision of this Section 11 unless, and only to the extent that, such omission results in the forfeiture or material impairment of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1) the

employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on written advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on written advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice relating to fees, disbursements and other charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 11 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

(d) Contribution. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this Section 11 is applicable in accordance with its terms but for any reason is held to be unavailable from the Company or MLV, the Company and MLV will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other than MLV, such as persons who control the Company within the meaning of the Securities Act or the Exchange Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and MLV may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and MLV on the other hand. The relative benefits received by the Company on the one hand and MLV on the other hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by MLV from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and MLV, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action in respect

thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or MLV, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and MLV agree that it would not be just and equitable if contributions pursuant to this Section 11(d) were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section 11(d) shall be deemed to include, for the purpose of this Section 11(d), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with Section 11(c) hereof. Notwithstanding the foregoing provisions of this Section 11(d), MLV shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 11(d), any person who controls a party to this Agreement within the meaning of the Securities Act or the Exchange Act, and any officers, directors, partners, employees or agents of MLV, will have the same rights to contribution as that party, and each officer and director of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this Section 11(d), will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this Section 11(d) except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section 11(c) hereof, no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to Section 11(c) hereof.

12. Representations and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 11 of this Agreement and all representations and warranties of the Company and MLV herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of MLV, any controlling persons, or the Company (or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.

13. Termination.

a. MLV may terminate this Agreement, by written notice to the Company, as hereinafter specified at any time (1) if there has been, since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any Material Adverse Effect, or any development that is reasonably likely to

have a Material Adverse Effect or, in the sole judgment of MLV, is material and adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (2) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of MLV, impracticable or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in the Common Stock has been suspended or limited by the Commission or the Exchange, or if trading generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market shall have occurred and be continuing for a period of at least ten (10) Trading Days, (5) if a major disruption of securities settlements or clearance services in the United States shall have occurred and be continuing, or (6) if a banking moratorium has been declared by either U.S. Federal or New York authorities. Any such termination shall be without liability of any party to any other party except that the provisions of Section 9 (Payment of Expenses), Section 11 (Indemnification and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination. If MLV elects to terminate this Agreement as provided in this Section 13(a), MLV shall provide the required notice as specified in Section 14 (Notices).

b. The Company shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination pursuant to Section 13(b) shall be without liability of any party to any other party except that (i) with respect to any pending sale through MLV for the Company, the obligations of the Company, including in respect of compensation of MLV hereunder, shall remain in full force and effect notwithstanding such termination and (ii) the provisions of Section 9 (Payment of Expenses), Section 11 (Indemnification and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination.

c. MLV shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section 9 (Payment of Expenses), Section 11 (Indemnification and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination.

d. Unless earlier terminated pursuant to this Section 13, this Agreement shall automatically terminate upon the earlier to occur of (i) the third (3d) year anniversary of the date hereof and (ii) the issuance and sale of all of the Placement Shares through MLV on the terms and subject to the conditions set forth herein except that the provisions of Section 9

(Payment of Expenses), Section 11 (Indemnification and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination.

e. This Agreement shall remain in full force and effect unless terminated pursuant to Sections 13(a), (b), (c), or (d) above or otherwise by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases be deemed to provide that Section 9 (Payment of Expenses), Section 11 (Indemnification and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) shall remain in full force and effect. Upon termination of this Agreement, the Company shall not have any liability to MLV for any compensation with respect to any Placement Shares not otherwise sold by MLV under this Agreement.

f. Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that such termination shall not be effective until the close of business on the date of receipt of such notice by MLV or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.

14. Notices. All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to MLV, shall be delivered to:

MLV & Co. LLC

1251 Avenue of the Americas, 41^st

Floor New York, New York 10020

Attention: General Counsel

Telephone: (212) 542-5870

Email: dcolucci@mlvco.com

with a copy (which shall not constitute notice) to:

LeClairRyan, A Professional Corporation

885 Third Avenue

New York, NY 10022

Attention: James T. Seery

Telephone: (973) 491-3315

Email: james.seery@leclairryan.com

and if to the Company, shall be delivered to:

KaloBios Pharmaceuticals, Inc.

240 East Grand Avenue

South San Francisco, CA 94080

Attention: Donald R. Joseph

Telephone: (650) 243-3100

Email: djoseph@kalobios.com

with a copy (which shall not constitute notice) to:

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

1200 Seaport Blvd.

Redwood City, CA 94063

Attention: Bennett L. Yee, Esq.

Telephone: (650) 321-2400

Email: byee@gunder.com

Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally, by email, or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, “Business Day” shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.

An electronic communication (“Electronic Notice”) shall be deemed written notice for purposes of this Section 14 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives confirmation of receipt by the receiving party. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”) which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.

15. Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and MLV and their respective successors and the affiliates, controlling persons, officers and directors referred to in Section 11 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party.

16. Adjustments for Stock Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any share consolidation, stock split, stock dividend, corporate domestication or similar event effected with respect to the Placement Shares.

17. Entire Agreement; Amendment; Severability. This Agreement (including all schedules and exhibits attached hereto and Placement Notices issued pursuant hereto), together with the side letter agreement between the Company and MLV dated the date hereof, constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. The Company and MLV agree that all exchanges of information hereunder shall be governed by the terms of this Agreement. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and MLV. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.

18. GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

19. CONSENT TO JURISDICTION. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.

20. Use of Information. MLV may not use any information gained in connection with this Agreement and the transactions contemplated by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved by the Company.

21. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic (.pdf) transmission.

22. Effect of Headings. The section and Exhibit headings herein are for convenience only and shall not affect the construction hereof.

23. Permitted Free Writing Prospectuses.

The Company represents, warrants and agrees that, unless it obtains the prior consent of MLV, which consent shall not be unreasonably withheld, conditioned or delayed, and MLV represents, warrants and agrees that, unless it obtains the prior consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a “free writing prospectus,” as defined in Rule 405, required to be filed with the Commission. Any such free writing prospectus consented to by MLV or by the Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free writing prospectuses, if any, listed in Exhibit 23 hereto are Permitted Free Writing Prospectuses.

24. Absence of Fiduciary Relationship. The Company acknowledges and agrees that:

a. MLV is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand, and MLV, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective of whether or not MLV has advised or is advising the Company on other matters, and MLV has no obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;

b. it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;

c. MLV has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;

d. it is aware that MLV and its affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and MLV has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and

e. it waives, to the fullest extent permitted by law, any claims it may have against MLV for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that MLV shall not have any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company, other than in respect of MLV’s obligations under this Agreement and to keep information provided by the Company to MLV and MLV’s counsel confidential to the extent not otherwise publicly-available.

25. Definitions.

As used in this Agreement, the following terms have the respective meanings set forth below:

“Applicable Time” means (i) each Representation Date and (ii) the time of each sale of any Placement Shares pursuant to this Agreement.

“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433, relating to the Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a “road show” that is a “written communication” within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act.

“Rule 172,” “Rule 405,” “Rule 415,” “Rule 424,” “Rule 424(b),” “Rule 430B,” and “Rule 433” refer to such rules under the Securities Act.

All references in this Agreement to financial statements and schedules and other information that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be.

All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433,

are not required to be filed with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to “supplements” to the Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by MLV outside of the United States.

[Remainder of the page intentionally left blank]

If the foregoing correctly sets forth the understanding between the Company and MLV, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and MLV.


Very truly yours,

KALOBIOS PHARMACEUTICALS, INC.

By:		/s/ David W. Pritchard
Name:		David W. Pritchard
Title:		President and Chief Executive Officer

ACCEPTED as of the date first-above written:

MLV & CO. LLC

By:		/s/ Dean Colucci
Name:		Dean Colucci
Title:		President and Chief Operating Officer

SCHEDULE 1

From: KaloBios Pharmaceuticals, Inc.

To: MLV & Co. LLC

Attention: Patrice McNicoll

Subject: At-the-Market Issuance—Placement Notice

Gentlemen:

Pursuant to the terms and subject to the conditions contained in the At-the-Market Issuance Sales Agreement between KaloBios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and MLV & Co. LLC (“MLV”), dated September 3, 2013, the Company hereby requests that MLV sell up to [ ] shares of the Company’s Common Stock, $0.001 par value per share, at a minimum market price of $ per share, during the time period beginning [month, day, time] and ending [month, day, time].

[The Company may include such other sales parameters as it deems appropriate.]

SCHEDULE 2

Compensation

The Company shall pay to MLV in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to 3% of the gross proceeds from each sale of Placement Shares.

SCHEDULE 3

Notice Parties


The Company

David W. Pritchard		dpritchard@kalobios.com

Donald R. Joseph		djoseph@kalobios.com

Jeffrey H. Cooper		jcooper@kalobios.com

MLV

Randy Billhardt		rbillhardt@mlvco.com

Dean Colucci		dcolucci@mlvco.com

Matt Feinberg		mfeinberg@mlvco.com

Ryan Loforte		rloforte@mlvco.com

Patrice McNicoll		pmcnicoll@mlvco.com

Miranda Toledano		mtoledano@mlvco.com

With a copy to mlvatmdesk@mlvco.com

SCHEDULE 6(g)

Subsidiaries

None

EXHIBIT 7(1)

Form of Representation Date Certificate

This Representation Date Certificate (this “Certificate”) is executed and delivered in connection with Section 7(1) of the At-the-Market Issuance Sales Agreement (the “Agreement”), dated September 3, 2013, and entered into between KaloBios Pharmaceuticals, Inc. (the “Company”) and MLV & Co. LLC. All capitalized terms used but not defined herein shall have the meanings given to such terms in the Agreement.

The undersigned, a duly appointed and authorized officer of the Company, hereby certifies, on behalf of the Company and not in the undersigned’s individual capacity, as follows:

1. As of the date of this Certificate (i) the Registration Statement does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and (ii) neither the Registration Statement nor the Prospectus contains any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and (iii) no event has occurred as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein not untrue or misleading.

2. Each of the representations and warranties of the Company contained in the Agreement was true and correct in all material respects, when originally made, and, except for those representations and warranties that speak solely as of a specific date, is true and correct as of the date of this Certificate.

3. Except as waived by MLV in writing, each of the covenants required to be performed by the Company in the Agreement on or prior to the date of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the Agreement, has been duly, timely and fully performed in all material respects and each condition required to be complied with by the Company on or prior to the date of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the Agreement has been duly, timely and fully complied with in all material respects.

4. Subsequent to the date of the most recent financial statements in the Prospectus, and except as described in the Prospectus, including Incorporated Documents, there has been no Material Adverse Effect.

5. No stop order suspending the effectiveness of the Registration Statement or of any part thereof has been issued, and, to the Company’s knowledge, no proceedings for that purpose have been instituted or are pending or threatened by any securities or other governmental authority (including, without limitation, the Commission).

6. No order suspending the effectiveness of the Registration Statement or the qualification or registration of the Placement Shares under the securities or Blue Sky laws of any jurisdiction are in effect and no proceeding for such purpose is pending before, or threatened in writing, to the Company’s knowledge, by any securities or other governmental authority (including, without limitation, the Commission).

The undersigned has executed this Certificate on behalf of the Company as of the date first written above.


KALOBIOS PHARMACEUTICALS, INC.

By:

Name:

Title:

EXHIBIT 23

Permitted Issuer Free Writing Prospectuses

None.

EX-5.1 3 d590927dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

September 3, 2013

KaloBios Pharmaceuticals, Inc.

260 East Grand Avenue

South San Francisco, CA 94080

Re:

Registration Statement on Form S-3

Ladies and Gentlemen:

At your request, we have examined the Registration Statement on Form S-3 (the “Registration Statement”), filed by KaloBios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “Commission”) in connection with the registration pursuant to the Securities Act of 1933, as amended (the “Act”), of the Securities (as defined below).

The Registration Statement relates to the proposed issuance and sale by the Company, from time to time, pursuant to Rule 415 under the Act, as set forth in the Registration Statement, including a base prospectus (the “Base Prospectus”) and the supplements to the Base Prospectus referred to therein (each a “Prospectus Supplement”), of up to an aggregate offering price of $100,000,000, or the equivalent thereof, of shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), warrants to purchase shares of Common Stock (the “Warrants”) and units comprised of any combination of the foregoing (the “Units”). The Common Stock, Warrants and Units, plus any additional Common Stock, Warrants and Units that may be registered pursuant to any subsequent registration statement that the Company may hereafter file with the Commission pursuant to Rule 462(b) under the Act in connection with the offering by the Company contemplated by the Registration Statement, are referred to herein collectively as the “Securities.” The Securities are to be sold from time to time as set forth in the Registration Statement, the Base Prospectus and the Prospectus Supplements. The Securities are to be sold pursuant to a purchase, sales, underwriting, or similar agreement in substantially the form to be filed under a Current Report on Form 8-K or otherwise with the Commission.

We also have acted as special counsel to the Company in connection with an offering through MLV & Co. LLC as the sales agent (the “Sales Agent”) from time to time by the Company of shares of Common Stock (the “Sales Agreement Shares”) having an aggregate offering price of up to $50,000,000 pursuant to the Registration Statement and the related prospectus for the sale of the Sales Agreement Shares included in the Registration Statement (the “Sales Agreement Prospectus”), and that certain Sales Agreement dated as of September 3, 2013 by and between the Sales Agent and the Company (the “Sales Agreement”).

We have examined instruments, documents, certificates and records that we have deemed relevant and necessary for the basis of our opinions hereinafter expressed. In such examination, we have assumed: (i) the authenticity of original documents and the genuineness of all signatures; (ii) the conformity to the originals of all documents submitted to us as copies; (iii) the truth, accuracy and completeness of the information, representations and warranties contained in the instruments, documents, certificates and records we have reviewed; (iv) that the Registration Statement, and any amendments thereto (including post-effective amendments), will have become effective under the Act; (v) that a Prospectus Supplement or the Sales Agreement Prospectus will have been filed with the Commission describing the Securities offered thereby or the Sales Agreement Shares, as applicable; (vi) that the Securities will be issued and sold in compliance with applicable U.S. federal and state securities laws and in the manner stated in the Registration Statement and the applicable Prospectus Supplement or the Sales Agreement Prospectus, as applicable; (vii) that a definitive purchase, underwriting or similar agreement (including the Sales Agreement) with respect to any Securities offered will have been duly authorized and validly executed and delivered by the Company and the other parties thereto; (vii) that any Securities issuable upon conversion, exchange, redemption or exercise of any Securities being offered will be duly authorized, created and, if appropriate, reserved for issuance upon such conversion, exchange, redemption or exercise; (ix) with respect to shares of Common Stock offered, that there will be sufficient shares of Common Stock authorized under the Company’s organizational documents that are not otherwise reserved for issuance; and (x) the legal capacity of all natural persons. As to any facts material to the opinions expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company.

Based on such examination, we are of the opinion that:

1. With respect to shares of the Common Stock (other than the Sales Agreement Shares) to be sold by the Company, when both: (a) the Board of Directors of the Company or a duly constituted and acting committee thereof (such Board of Directors or committee being hereinafter referred to as the “Board”) has taken all necessary corporate action to approve the issuance and the terms of the offering of the shares of Common Stock and related matters; and (b) certificates representing the shares of Common Stock have been duly executed, countersigned, registered and delivered, or appropriate book entries have been made in the stock records of the Company, in each case either (i) in accordance with the applicable definitive purchase, underwriting or similar agreement approved by the Board, or upon the exercise of Warrants to purchase Common Stock, upon payment of the consideration therefor (not less than the par value of the Common Stock) provided for therein or (ii) upon conversion or exercise of any other Security, in accordance with the terms of such Security or the instrument governing such Security providing for such conversion or exercise as approved by the Board, for the consideration approved by the Board, then the shares of Common Stock will be validly issued, fully paid and nonassessable;

2. With respect to the Warrants, when both: (a) the Board has taken all necessary corporate action to approve the issuance and terms of the Warrants and related matters; and (b) the Warrants have been duly executed and delivered against payment therefor, pursuant to the applicable definitive purchase, underwriting, warrant or similar agreement duly authorized, executed and delivered by the Company and a warrant agent, and the certificates for the Warrants have been duly executed and delivered by the Company and such warrant agent, then the Warrants will be validly issued and will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms;

3. With respect to the Units, when both: (a) the Board has taken all necessary corporate action to approve the issuance and terms of the Units and related matters; and (b) the Units have been duly executed and delivered against payment therefor, pursuant to the applicable definitive unit agreement duly authorized, executed and delivered by the Company and a unit agent, if applicable, and the certificates for the Units, if applicable, have been duly executed and delivered by the Company and such unit agent, then the Units will be validly issued and will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms; and

4. With respect to the Sales Agreement Shares, when: (a) the Board has taken all necessary corporate action to approve the issuance and terms of the Sales Agreement Shares and related matters; (b) the Sales Agreement Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers; and (c) the Sales Agreement Shares have been issued by the Company against payment therefor (not less than the par value of the Common Stock) in the circumstances contemplated by the Sales Agreement, then the issuance and sale of the Sales Agreement Shares will be validly issued, fully paid and nonassessable.

In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware (the “DGCL”).

Our opinion that any document is legal, valid and binding is qualified as to:

(a) limitations imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent conveyance, moratorium or other laws relating to or affecting the rights of creditors generally;

(b) rights to indemnification and contribution, which may be limited by applicable law or equitable principles; and

(c) general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing, and the possible unavailability of specific performance or injunctive relief and limitation of rights of acceleration, regardless of whether such enforceability is considered in a proceeding in equity or at law.

We express no opinion as to the laws of any other jurisdiction, other than the Federal laws of the United States of America and the DGCL.

We hereby consent to the filing of this opinion as an exhibit to the above-referenced Registration Statement and to the use of our name wherever it appears in the Registration Statement, the Base Prospectus, the Sales Agreement Prospectus, any Prospectus Supplement, and in any amendment or supplement thereto. In giving such consent, we do not believe that we are “experts” within the meaning of such term as used in the Act or the rules and regulations of the Commission issued thereunder with respect to any part of the Registration Statement, including this opinion as an exhibit.

Very truly yours,

/s/ Gunderson Dettmer Stough

Villeneuve Franklin & Hachigian, LLP

GUNDERSON DETTMER STOUGH

VILLENEUVE FRANKLIN & HACHIGIAN, LLP

EX-23.1 4 d590927dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3) and related Prospectus of KaloBios Pharmaceuticals, Inc. for the registration of its common stock, warrants, and/or units and to the incorporation by reference therein of our reports dated March 29, 2013, with respect to the consolidated financial statements of KaloBios Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2012, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Redwood City, CA

September 3, 2013

GRAPHIC 5 g590927g37t28.jpg GRAPHIC begin 644 g590927g37t28.jpg M_]C_X``02D9)1@`!`@$`8`!@``#_[0H>4&AO=&]S:&]P(#,N,``X0DE-`^T` M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0`` M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`& M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4` M```!`"T````&```````!.$))30/X``````!P``#_____________________ M________`^@`````_____________________________P/H`````/______ M______________________\#Z`````#_____________________________ M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0` M````.$))300:``````!M````!@``````````````3````54````&`&<`,P`W M`'0`,@`X`````0`````````````````````````!``````````````%5```` M3``````````````````````````````````````````````X0DE-!!$````` M``$!`#A"24T$%```````!`````(X0DE-!`P`````!X$````!````<````!D` M``%0```@T```!V4`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4` M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P, M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X. M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`S_P``1"``9`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$` M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@) M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D M%5+!8C,T)E\K.$P]-U MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$` M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D M8N%R@I)#4Q5C+RLX3#TW7C\T:4 MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1 M`Q$`/P#J_K3]7'7TTNZ5?=AYCGN:UM=UC&617;:RI[18VMF^RMGZ99O^+;K] MMYR.DYEMEMA_6<9]SG/?M]K,BC=:7._1/V6;/^%M_P!&NNZC_.X/_AD?^>[E MYY];<6_ZM_6NKJN"WVWN^V4MX:;)V9V-NU_GVV;W?^&_^#4^/UQ,#N1*F5/=7)J>VNVYYJI!K<6P"2WU&^HZS;^]10VVW:_\^OTUPG^-"JNC(P*:AMKJP[6, M;S#6FMK1K_)0P#UB_%3V_0>DXV%@XU@=9=D.J:;+[K'V/EP_8U[W,W,NV;_`/C:UWU631=9=54[<_&>*[A!]KBQE[6_ M]M75/7F?5:S]4?KHS.8TC"L>6Z^ZO&Z=U`9PI&'D-#:K,?[/O:[[17>RS*]+'9==E?T6];= M7_BQRO\`TVXW_G_-6-7TOKC.C,^JYZ12:6M%7[5%M?I2-?VE]F_I?V[=^G^C M_3/^U/\`A$^.AO3:/AHI_]#M/K-]8^E=*RNFTY5[&V.R6NL9N$UU;+&')M;^ M;4U]E?\`JQ/];>DU]>Z`\XA;=?3^L8;V$.#G-!W5L>W=N^T5;ZES%'\[?_77 M1_4?^@9/_'G_`*EJEC5PX+XE-'_%MBY#^CLSKW;L?=:WIS"/HUO<'Y-D_P## MY+/;^YZ?_#+`_P`9V=B9/5J<:BUC[,;'>RX!P.U]CO;4[]VS]'[F?U%VW4/_ M`!+._P"*9_U3%R>+_,CXN_*I(?SQO?6OW4O<=$S,7-Z3B9&+:VZIU3!N808( M:`YCH^B]CO:]GYBY_P#QEYN+5T)N(^QHR,B^LUUDC<6L=ZMEFWZ7IMV?3_?0 M?JO_`,NN_JO_`"5K.'],O_U_.*]_P"6 MJG<_QX/NR.H666%O`^JG]`N_X\_\`45+2S_Z!D_\`%/\`^I*.OO>G MNIPOJ'1E'H6-F9AW/LJ;5B\RW%K+OLL_RK6N]3>WZ=/V;_1+I%2Z%_R)T_\` M\*T_^>V*\F9/GEYJ<6HC_GCE#O\`LW&T_P"OYJY^[Z\]1S&!_3FX^,ZBMV3F M-L>+F"@M8[9ZDXMK.KT6G[._I_HW5>N_]/D+JV?\N7?^%:O_`#Y>N;^O?_*' MU:_].;?^J:G1X;]5;#?R4__9`#A"24T$(0``````50````$!````#P!!`&0` M;P!B`&4`(`!0`&@`;P!T`&\`*?[WUZ!'EJ7^Y<;G]B-+?\#3?F_P!* M7(WA\J^HHCO<^\*I&LZ3JM_JPM#FB#FD@C,W':-HYI MXT$^UUU9;*L0J),PL=Y#M'(C$'>"%`X$$X+*V7W7 MC-\7&"``8XI(\E?C\9_BX<=NU"L1VCP_H@XN0!XL*3#>D5;>7QG]["&!$"E5 M;0#C\/"?WL#8#`(2MO?S=Y?=*QUP+=::]-5S)^W=:031.X-V*EI-Z+*602FF M*S:CJ,5^O1EX.TNS_`*KBU/L1I;_@:;\W^E/R-^;\ MJV@T)5M3]93\K,-32Y8Y,C,!B&4@FP0W`#\G:IY^5GC1[E4R: M^MGUFKF1$(S3*LZDF].%5F&-4(LD`.HL1BY!V"9!,1N<`'*P-/WWP^NU1)H;CI MF1253R`UQZTLN.XN@"V.[,(<2$\9#YB`!\JCWBG^]]>C_P"9?[EQ:7V(TK_P M--^;_2G9&_-^53Y5'O%./5]>@?9J7^Y<'V(TM_P--^;_`$I%R2(1:R%:5G.U8>.HRA(9VX,V0D:@DR1[A45WBB:@-&39- M=Z[%-04DA(DJ=/P=06S0&FJ05=SLU."XP8QK8O>>#1'8-Y,`,(G$`H6L`Q:F M/*'[MK6^2%:FN1WM&I)S4)TRB^2H:"B6,*@J(#O)M5YZ0DGSM(O`!SIHB;AW M0X`J:IU=ISO#ZIH6C$K=G*^)`]3I)YEJ+K=$77.9[6*.[]EC6+W=J.ZNI'4=DIZ M+N\T>ZS=?-"&:/S8&'XQ3208P;!;S$TB:V3/D3GRFS&,>UQ8[LN`():88P=L,-Q0(1QV(*]XN[C[PII2; MY]8;O4[\RE9LT5EV4!=!NQ80DTHF@H=-B%0TT)W,*LX6`I2JG8NDPSS,`!M" MPJ#5NE73VMN>B*5M.=KI9)N7O9-.]S*HM#>/4C?FB MZ_I!\9E,0TC4J2I3%'RVDE&/VJ*S"8A9-N(+-'C915LY1,!TSF`<7);M-Z(N M]')K[=:*692S!$$-^$$'$$;""`04_*TX@8>58K^51[Q3_>_O1EX.TNS_`*KC M.^Q&E?\`@*;\W^E+D;\WY5L]I`U/][-K4OE3EB;2ZM[MDG)=L\F9R>EZH52@ M:/I*).V+-53.J-V*SCH+(SQ%%--,AE'#MPB@7(RH"'C7ZRZ&TY;9USN%AD=T M"&M:UO6>X[&C':<3$X``DX!(6L`B1\J9SISNVM7I(AD%6=[)JK>3W,)#(JT[ M#TW&Q`NA('/%9-Y)S+/`;E4SW!45WA#A`!Q3DW5UB,QW<:&H1+W9BXF'.``B MH\S?F(GUEJ`J*UML:4H*J[E57>&H*=9NFLE3`,"%:`N MW;NB-R;@`'-(EX\\:;7U4JLK:BJDTC*>4\B$MD?*.$HZI*: MED6@)24.]5:*D`V1%4EDE$52)JIG(6\[-8]!Z@HF7"UV>F?()@06P"]ZI>.N*>MK:[4?J%KRO*K>A'T_3%.2ZDA*R+ M@$SKJB1)-J!$&K-JD=9PX5,F@V;IG55.1,AC!FUFE=%V^FFUE=::252L$7.< M(`?'M.P#:3@,2@M9P^5,K:9=`/>OS",'5.IWO(KDT&8JK60,@$#+I$,14&2;],-[R53<.*@O&J=$,[V39=(29N!`F/Z@Z0T1= MT1AT)CC+&`;BF$"@(%R'//V3^]BK,(0*C*"IW\5^;R:==&U'5U8^XU46QJ]] MJ#HJFG=04H^%A(N("0H2Z$B\BE%A3/O-'#V(;*F+EM.B4>+%A^&5JMUVU#/I MKE2-G4XI'N#78C,'R@##D''X4]D"8$8(G&EZH9NK=-FGZJJEDW\7:1):&R65,P- M`V`![@`.@!-=M*SKF/+XS?%QY\<-J:EIN^7U?ZJYW419_NY]%X$[R. M'AD:]A[]6Y6N,V,281@HVZ5Q8^HDY4J@.`Z'6"]/-(XDL14-XJPN4D^<#/G0 M^%C:AXI:0F/--,M1X9LRN8YY+(90YH,(F"7*W;R7_ MT'\LQ\[/DR#XH8:`A8*U.67@]1.GN\=D:D0;.HVY5O:GIA,[ELDY"-EWL8X& MGIYLFJF)"R-.SY&S]J?A3C9Z^;:KK;KE)<0Z3.:XXPBT'K-PW.; M$'B"0G-,""N=Q=322_I31!I=UB0*3I>G[HU#]C9H(B.";B^;>ZR!=QM=Z)ZPE4BJPY9.Z5FP=K)IG4CW3M,; M@TG'E.4!64;/WA)A)$@B?<6?*Y;I#"%$>+NG\CZ745.S!T)4V''S''I'4)Y- M&],F##-#%-=YCE\//9P9!M_08I&'!0*\S>?[@?$P0Z4*S9@.PV[[0;=G#\$< M$(H7CF;SO;R#XO)@@A8GOM>:CM/-G;CWMN$_Z'1]LZ4EJJF!*9$CEX6/;F%E M#QH+BFFO,S\D=%BQ1W@%=XX33#:8,9MMMU1=:^CMU(V-1.F!HX".UQY-$7.. MX`E.:,Q`2!/>L6IKZ@;G6@KR\XJ^GK4;:A?4%>5!0Z@D@*FKZO*N/"4(S157 MJF^RQS-XK5\VJU0ZBC,W_I/<#XF*SATJ)5F;S\O:#;^AP00IF/G>WD&S]#@AN0J,`B M&0FW@\&0;?T(8((7-L[U6R<-8#7YJ0M]3,8UA:65K-.M::B(])-NPBXBX41' M5HG&Q[5(I4F1Q.))ED MLB3O)@"3Q62#$`D(>WC]SXN-L@EB."Z`7<.61@[4]WM;BK6C)HG4U[I>I;D5 M/*$;D*\>)A.2%-4TS77$@J*-XR"A$Q3(([I#KJ&``$YL^6O$RXS:_5=9(5YV?+D&S8([/)Y,5_L4:FW9Y7$.>P-NTWV MN!"GE>?ER9!L_08(10IY7G>WD&84/V6?((!X;3=%2-5D=M44TWU36F:D,^KZFG9P,D5UV M?9)'G&.^"JB9F;A!`H&>GSLGPSU*^S7IEMJ)G^WUA#(;FS=C'#AF/4=LV@GL MA2RW;CL2'WMC[GQ<=.04L0,((U/<%7N@+-]X72T34CANR8WQM]5UE&4B\630 M;LJBF9"FZSIA'?.'EN9V>H5"*;D#:=R_3+QXKKQ1MLVX:4G/D@E]--9.@-[6 MAS'?`UY<>0*:X1:8!/Z9F$/A\(#LR+X/N?[@?$P0Z4BK,WG9> MT'Q1P00IF;SO;R+\7DP0W(2R_P`YEH&`E+"Z;J_3CDW->QEZGU`0SAN@*DH[ MIZL*+FYJ4C4R(DYYVF,S1\>*9,C;BAQW,A4-O7!X/54V7=;Q2EY%*:8/(.P. M8\`'E@]T>C'8II>\+>7NA.[3L;'LMV8ET4>^,0-B,)F/A#BVY!R[?@XT."B59F\_/DR#XN""$OS\Y M)$PZ":#V_P`:"W_$&S.W%X?``8M+PA]Z*KZE,]))4LKM(O6CX1]4S3%D;=_> M^V4]]J.-"OP_WV]?6IOI')CNT>E;&^5Y_AVY!GQ?:X\J":E0^]ZD+M M:&>\JTZ=Y#2M%EK:@>R*%%R)'17:,.2I64'65'5)24M*M&ZZ<"^J*WM5](AU MU0-SKILX,5)4K54@W;H-E#J71]WT?/J>[J^\SB$(Y26N:X`]H-F-@\<",1F" MG9`L@LROOG-&F@E+G>QM@;W.:P%L(I4\\=T,T@@>;IMU-6ID9MZ[!GO@&:I8 MTRF[_8L]F,!O@Y>>]#7W6F$B/:`>3#\6$(_E>5)W6.W!`MCZTU)*3%7=\VZM M^5L9EK.MT]@8\8:4-1,R$G`W2D*L0(Z*(O4:5IH8B%@#21C`11]+%3*H+@AR M!9+Z>T"7(\/&U40;=,#C$9Q!TL-,-F9T7OR\&G<8J3#LX[%__]%_0#9CEF'B M_389!"\3FS(I]P;BRXO9PL`A+K=V_ILIO5WW'B.G^I1:MR5XZODWIZ9=)*+$ MIJM8V[55RU%5.4B)TEU"P53,FJZJ9#DZ0W*HB8=Q0P#:NKKO.L/B.;M)VRA) M+A\YAEM#V_E-)'(X[E)'*X1X)+*N*+J6V]:5;;VM(I>"K"AJDFZ1JB%=IATF M*J"G9)S$R\>L)!,0QVC]HH3>*(E-EF`B`@..B::ID5E-(JZ9X?3S6->T\6N` M(/E!61Y5D#3I?*K]-%\[77WH1825+;&KXNI6S7GEF:$RP;J\Q.TU(+H?ABQ% M402[F.>`7:9JZ4#CQBW:V2+S;:VV5(_4SI9;'@?-<([VN@X7@H)[T^C[E4A!UC3ZZ@$*N1A.,$7I&;Y,BARMI*/.H9NZ1$=Y%PD M=,VTHXXVKZ&?;:VKM]4V%1)F%CNEIA$/8(<.`H5;W'L\6WBXL\$$(66J!='57J]LIHL:;LE;&T9H359J MH;D,@I'RC2FI#_P&M1-(J-W"+I"J*_31G'[%00!Q&109AD8,;G9@;)8;EJ(X M5L^--3<07#]=-!&(RLBQIW.N'9O+(`#3U%Y!NY_N@5UQ M9CBV/!X`:?N$!_FSZ.6I)?9YQ2YFSD^\'%M*3RKH2]Q#L[KO3QP!E)WISV?Z M=;D\H8Y6\3!_W6[8>;)]#+6,_M(O>_\`1E^FQH4`F*;V7@VAGL#E'EPL!Q0I MO<>S9LX-O']M@@A6!L]FSBX0Y?NL)`(7/Q[^W;WF%W\\OV)6E^QS_?N?4WL+!"@&S'+ZF7]5@@$*`?;];]-@@$+U'S-G),W4?(- M&SYB];+LWK)V@FY:.VKI(R#EJY;J@=%PW<(J&(<5C.$"5M@)\A'V?!^FQXD!Q356]EX.`!V!R>S@@ M.*%-[CV<(AP;>+[;!`<4(,MT(9EK6[TFV=NET"3%EN[OI5.\%P`W4W\)-ZC[ ME&;)VPI.3)ES:3ZB8.&">1,)CF*LDJ@HF!3B([]13':=T76U;3EN-V?W4O<1 M3RX]XX;X/<[)Y05,.JTXXE&:S`ODAQ<@C],V-`@%$IGQY%X0VY!GQ\O#LPL$ MBO>SV;/;#9_YV"`0E]OG)8YZ"J$_XH+?\'^KB\/CSSQ:7A#[T5(_^#,]))4D MKM(OFCTV6DS3%_P_6W;U];F^DV1M]5- MU+J55%450-&1II6HJDF5N89,&PK(M6Z92EWUW;U^]73;M6Z)%%W3E5-)(AU# ME*.'1455<:J10T4ETRJF.@UHVD[?@`$23@`"3@$@!.Q#\T?]X!IR[T1YJ'MI M2]JI2ZCI5BZ+6)!(W1;%* M0$#`"9MXH8V?359KS5E/;YKJ[T7^CGH7.]?[GY-U!T'G>;V\US'EX MTGV!J/V_[+]6G>WM+VXRW'$?D.,.AP&Y2RSA`G M%+:9AX.'E-M]S;BWE(F^_FWVL@)JEZYT4UA(I`^I`)*YMH.DN$TU'%.RDD0] M>4LR35$IG"D9/2!95-,F\<2/G1\MU(1"A?%S3_=SZ;45.SJS(2YO)P'4<>EH MRD\FC>H9C?.34F0>:;Q?6Q2D>042LP!GP&]H.#`3"&"18YN[=&D+)6ON!=VO M'AX^CK;4E.UE43DH%,N$9`QZ\@N@S1,)>DR#P$01;(@.\LNH0A?*,&,JAHY] MQK*6AIF1J)TQK&CFX@8\AM)W`$I0(F"TV[N*UE:0EI*CU"7ECSM+_:O:J5OK M(%/>=PV!+1?.6P#UP[.;!R]7J*V#F`Y]OZZ M\`#BX_!\QT_7_6SZ.6I)?92Y>SP<&W+,VSVLL6TI%T).XB`![KS3OF!O[YWI MX-O[NMR<)OOI=OQ9/H9:QG]I%[R#P'\7UL:#'D/C35,@\TWB^MA8\@A3( M/`;Q?6P1WX(4R#P'\7UL$8[@A<_+O[1`.\PO!X.R5ILMH_YN:=RX,\=2^&'N M=;_QYOI'+)9V0@V[.#+@XLS;.7++%@)QV%=(7NC0#Y-S21Y)L_1D.8@'@J6H M,+D$/JXU+;P35,@V9E-P#Q:;VPY<\`QX(59!YIO%];!'D/N\B%,@\ M!O%];!'D$)=/YQ/I#]*^G"FM3M*1!G-;:>I'H=6';)J&=O[158Z1;22JB:!# MJN^R%4G9O2Y@!&K%U(+&$`SQ:_A/?O4+O.LT^9"FK!%O`36C#HS-B.9#0I9; MO-21FSPE;GW"T<59+%3I^YS1[_HZ34$AGZR21+FP^8XG( MX_BO.7\L<%',;A$;4Y'D`[+ZV.?X]"@4R#S3>+ZV%C#<$+"VHN]M*Z;K% MW4OK69R%IZU]%S55.6RKI-B:7>L6IBPM.-'*I#D3DJFFU6T31%QY`I6B)`6J7=AV,JJTVFQO7%U`4< M7UU*U3-ZBKTOW*`!(EJNXXH2,;3RRYS*N"M:5IHC1H1N)N;;K`MN%+O&S]O6 M5RD5UX-/0P%LHY8IY(W99>!=LVN=$QWB$4YYB8(BV0>`_BQJL8<$Q7D&7`;W M,_?P12*L@\!_%];!'D$J7X^DDJ M25BZ"+WH]`/5,TQ;##^]]LYP!_H\IW&A7\POEYV?XJ;Z1R8[M'I2]/SF:Y57 MD@])MAX5^JTIBNY^X-;U&P%0$&\Q.4L%'TY1G2UP`#=$BRUA*',F8W-"HJFH M8-Y(@A:O@[12#.OMTF,!GRF2V-/!KL[GPZ3:;$K^4H^HF9TGL2Z75BFBBR0BHS M>"U2(Y162+N#CV74%VT_4FIM549;B1F;M8\",`]I$",3P(C$$'%#7%JY^$;3 M=6LZLK7N[QJ,RU,U#KFMA!EEE1$[>.JBC7MW;*J5*Q9BKT1NI-1==%5=@`@9 M;H#<@F$$RY=3OFR'2*?5?<_^X9;)AAO+7B5.RD[<"R`X9CQ4^,8[U__3?Q#( M!V[<)Y4+Q,.1#_<&^E@0@Y]PQ_RT;0?]LKS^/TL5;C?O$SWPK_HY7HVI[^TM MWM<&E^`UBZ7KLV#FRLT7U6TXX<47,/2JH#*(!TI-JQJ!JB5V5 M/REV*BZ(YE5,`ZWIV\S;!>J&Z2RWI+28<'0.Y(PY2"N9?5=+5 M!0]45)1=5Q3F#JBD9Z8I>I(5\3FWL1/0$@XBIB,=IAF!'+"0:*)*``CD8HX[ M#D3Y-3(D5,F8'29C`YI&PM<`01T@K)C]V"RQIBO]5VEN_EK+^40=09VVE6QT M\>/3>+,4JAA-\S2IJ5?.4`%4D;5-/.74>X$`')%P80`1`,8-YME/>K76VNHA MWUBV(C MBGQ'/XET).XBR^2[T\9\/6=Z9VD7K&A^5, M5CQ>Q]4<'E0IQ#[7@Y<'E0H'#X>#P>$,'E0N?GW]O_,PO!L#]B5I=@\7_AS3 MO)CJ+PP/_3K?'^\F^D[BP(CBG%P@=OQ+I"]T=G\FYI(V99VR MSXO\I:@Y,9VW=*(T`Y`/+[G#C4X)BO/+='D'Z8X$+Q':( MCRX/*A7GL$/#Q[/>P00H4S@\J%!][Z6#RH7S-;4;3EQ*,JR@* MQC$9JDJXIJ9CEC)B10J;V.>*)B)1`P`;,!`'M/!S2"#Y"`E!ABN8MJYTZU!I0U'W5=(1D-+. M6YFQZAI-R8LC2-1E2$H%($Y3CMLX,4@F*FHWR.!'QK*#H@%8YL[=2K+&W6MU>*A716=7VRK*GZU@%#G7*V6?P$DW MD",)`C=1%5S%29$3-G:.^!5VJJB9LRF$,9EPHZ>Y4-7;ZD1IYTMS'<8.$(B. M\;0=Q`*"05T^+!WDI74+9>V-[J).H-,7.HR#JZ+17$@NV`2K--9W$/P((D)( MPS[G6CDH"(%71.`".6.-;C03[57UEMJ?[:1,+##88'`CDX0(Y%8SA`E9>'Z@ M?2#&%Y4U!_URB.JW5II?[OV+.+NAX=\TU>ZK$"F!1BZM7;.8*RMQ;N:9G*+6 M5C+BW'52(\:G,"B"3=NY*40`!#>M-GV)8[UJEW^)<#2TW$39@C,F`[C+EQ@> M)(4K.J"2,47XH`4`*4``H```4`````V````9``!C18*)>0Y".S8&"'-"G%XO MZK`A5@\J$OU\Y)V:"J$V?QH;?[/_`*<7AQ:7A%[T5./^1F>DDJ65VD7G1]_! M,TQ?\/MG/]GE.XT*^_MR\X_YN;^FY1N[1Z4(CYP3HNK?4=IYH:]5L(E[458: M:WU62<[3,:DHO(R]LJQ:0IZLDXUH@BJXD)*DG]*L'G,EWK/<3W,0 M5][J/^$=RFU+'7JME2Z,&)$LESW#>(EK6M_&B[HBD;+X MH'L=H?U-(Z$:R[PM[3-2JUI):B[:W*IF822$*G8VZA(N[$C7%XWL4*.\>(E; ME5!3QFJI2"8J3)PZ,F#0Q5AL=^H[.=3T^DVS&>K"DF2W#S3,)E!DH'YPEM?$ M;(D#M*2+8Y8X+__4?S`?9\8A],^&)5X''R#\/P#^O^CE>C:G/VHQV>SD^CBW\:`FI'_P"<,:-_0YJ- MB=3M(Q:36@M16\G4Y&;I/5#"(B( MXZ.\*=0>T+3,LM0Z-32=F.^4XX?F..7D"T*=ABW$XI>'VB^[[V+7`'!.B$Y+ M\W&UDFK&VU9Z-*OD-^=M85]<&UQG"YA5=T!.2Y.U,$B*SD3'&FJKEBN4R$(& M2$F8`\E+9S]XMZ?]7K:?4%.S]5/@R9R>T=5VSSFB$>+>)433AZ.H"EYVL:GE50,8D?`4Y&.9:5=`FF(J+*),VAQ(F4#'4-D4H"( M@&*CIJ:=6U5/1TS,U1->UC1Q;6 MG4R5T7,:\'GG5#V::-QCK&6Y:+*D3F))/YRV/[ M\.SG'^]ZB^'_`+?US[..C/!\1T_7Q_U9]&Q32^RES/:+[OO8MF`X*2(70C[B M(S,,#PC[OQ\+`H4W@Y?=^/@W)%`'V?&(?3/@Q2KGY=_;_S,+P#D'[$K2Y__`&YI MWV<=2^&`_P"FV_Z2;Z1RR&D90@V^T7W?>Q8$!P2X+I"]T<.7=NZ2/]60_P#> M2?X@,'TL$-FWE'[8,'!"K M>#PC[OQ\$$*\^4?&/TM_/`A?Q7L2LZGG$I*@*0U!.Z?LC&$ MAH6,7@+8NVCMY3[%\[BF3-S,/EF)$55EW:CA7G#&`I]W(,;WK?3=+IKV!3R6 M$54RES3B7$YI@(#B`3@(Q$!!/>`(01>][E'W?J'QHB8KSY1\8_2W\\&Y"5*^ MM*DXPQGL(LSM!=T6K=4X'A'ZSV0MU5#XR9N9;IQLPJ[B5USE%1 M8\BP2W@*D4,7;X0WW+-K-.U#^JX&;*C\X0$QHZ1!P'X+CO4LLX02BOM%]WWL M7QE'!21"<*^;;:N1J&B+EZ-:J?">4H-1U=FUQEE%#G5HZ:?,HVN:?2%1P!$T M8"IWC-\@F0F\?K=R81W4@`*"\7K#W-31Z@D,_5S?U4S\<`ECORF@M)CYC<,5 M',`[03.]4U/"473-0UA4TDWAZ;I2#E:DJ&7>',5I%0<&P<2DM).CE,(E;L6# M514XY"(%*.*;E29M1-E2)+"Z<]P:T#:2XP`'23!1`1,$+CNMJ;G;EQ5[-?-Q M8YPUKS6372LU1;20R5SDV<>WC^WSPNY(JWN4?=^/A$J7X^+ M[8<6GX0^]%5]2F>DDI\OM(O>CX3R2(;5[>Z+[O74!43NKZZTZ4Y'57(*'6?SM MO9>IK9*R+E94RSE[)Q="SD%3TM)NE3B95TY9K.E##F90<;;;==:KMKSK->Y51UA< MB+14#X!S4K6%02M'.%4C9&345CU%$S@!BF`P`.)J[Q`U=<)3I,V[.9*.T2VL MEG\Y@#_@=!!F%$_Z$QZ#U=T1KT#HW0^@/6C&.^/'IWIF_:O_5?R`1\[QB/U0RPW%"\3B.X?ROL#<8^#E# M!BA!R[A?/Y-*T&W+_#*]'&/^=FKO!C?_`!-'_<*^']W*]&U.=M1CLQ\X?&/O M8T#%-6EO>"Z3XG6CI0NG8YTFR"II*'4J*VN"@`B;&P:6OX:[+,`\Z6[!XAO('6'X0">QT"% MS19R%EJ:FI>G*@8/8>>@)20A)N(D$%&S^*EXIVLPDHU\V4R4;O&+Q`Z2I#`! MB'*(#M#'8,N:R=+9-E/#I3@""-A!Q!'(A9&'!9\TBZCZGTE:CK3Z@:3,Y<.[ M>U2S?3$0W7!J-34@]`\965*J+G(LDD2HJ8>.FA5#$.""BI50#>3+EY=^M$F_ M6BNM4^`$UA`)\UXQ8[\EP!AOA!!`(@1@G?=8%Q837-5FEC19:&>"?MKJ"C:7 MU.:B9V)<+IH%TETL[C:BC*=]15\G+64A=3R&G_5.!:70.!$IL7'IPQ`4(&7,2C&MD$6C=!JU22;-6R* M3=NW0(5%!!!$A4D4$4DRE(FDDF4"E*4```#(-@8T(EQB7$EQV]*B7]\Q\[W1 M^J&$Q0DD_G+G\,.SF9OXO47MVC_C_77*`XZ+\'_=^X]O MG^Z;WL:%CS3%68^=[HX,4*9CYWMYC[V#&"%-OG^#C'P^Q@Q0N?GW]W_,ON_F M(A_@E:7;P_N<4[QYXZD\,/M34>=L:6F(G/_((R#\I^6(WMS<%)+&,=R'=\V+_`&A]3N1OW7J3S':'^)@; M./&V>,?[4LWU=_Z:=-W)G3,?.'QC]0,4YBH5>W;Y0\7&/+R9X,4+#>H6RE*: MCK'W2L96Z::E-7.HR:I1XX.V(\4B73]H<8BHF3=8R:9I2F9E)O(,Q$Q=QTV3 M,`@(9XS[7<)]IN5%,6.PX/`)XC!!$01!/#=X[=)6_5`:;]'%E*E.O+]X'4L,TE:E@W`D=P6EB M#CV==7AK5DXW%6R8R-*.40S.`!CFW2='[,JKOJ"XROU=J88- M/G5+B62F'H=%QX$-*A8,I)(V(L=+TW"T;3*101'SO$(_4#+!CS0IF.7#X-N8_;>W@Q0IM\[W1][!BA+\?.2L_ M4*H/;_&@M]QY_N<7A][%I^$7O15?4IGI)*DEGK(O6CX1]4S3%MR_>^V<\/%; MRG?!R8T*_?MR\P_U@QE8V3!<8Z39/P:KJ-G70GB+KHSE$XIJMU^8.IS*Z1RB!B&R,40',-F!P< MR&=I$1$1B(CBE@5^5VQI/>YKM53_`#W:'LCS774=SG:OHO3>S.YTG>[0]"_# M="RZ3S7E;F[MQ)W4[;W+X9,VP]F,,VSLQPCLYH@>"__6?R#:/%X]O_L\-Z?O MH7P]S:\A+76XK^Y=3.$V=.6^HNJ*VGG1LQ!O#4K"/IR25R!,!-S;-B<<@VCE MD&,BDIIM95TM');&=-F-8TJ^[YC*49OFZTS;6ZEQ MH.=8%/\`AV8U#+%K:.643W#"5%ZWJ(VX;@,*9@XAQ8'BK2S)&JWSG-A+G2); MFGCE&0_`6_&$^8(%'3S^Y\?XO%;XJ-5PAEL]H1\`_J6#I0D8/G`^C4;':H&^ MHFDHDK6W6I,SJ5EQ:I&*TB;N1:*7:Y!015,)5:N0%.8`=TH*NE7@AL)D'27A M7J#VE976B>^-71X".^4>S^9BSH#5DL,6H`.Z`?0/OXM+'BGI[WN#])\E9S2J MROW<`D@XN3J`CXQW!#-N%7;RF;)P*KP+=4_&F64<]!B9P':\T1%,2$%!ZV`2 M%,GD',OB=?&7"]NM=(6BCI"0SZ,OU/ MEQ6JB4`<_-\?XO!TH2/?SDV&;*D4>4_I\IHDDF41$4%).M*Y?-B' MV%R,9J8I\O`8/#CH[PBE/9IVLF$8/JW0\C&#Y5D2NREY=T.3W??Q:V/%2+H+ M=PO(-GG=A6*;(*%.M$5#>6/?$`V8HNE;R5S*IIG#=-D8S&314]@X8Y9\36N; MK.YEP[3)1'1W3!]Y8S]J,1G]SX_Q6-!Q^Z*8H(\'P>#P_B\'W;T*9[/L?'^+ MP8H4`?8X0X!Y?_5X.G[Z%SV^_5G(V>[S&^H1ZY'`0\7;*"?"0]M\^F_JM6-,[;NE$:XA^#LRX_Q>-23% M?F\&T/JCP?@_>PJ%0CM'X/C_`!>$Q^Z*%^+451P5(P$U5542T=`TW3<4_G)Z M;E72;.,B(:*:JOI*3D':Q"HMF;%F@=110P@4I"B(XDE2YDZ9+D26%TY[@UK1 M$DDF``'$E*`28!<[WO7]?+W7IJ1=ST`NZ1LE;`)6D+-1;A,R!W42J[1&;K=Z MV4327;R=<.H]!<4E`WV[-!LB8-],XFZKT-I<:9M#9'\'@Z4)-+YR!I"[&W4M]K"I6.32I MVZZ#>V]R^C))I)M;CT['.7=+S+@2`0ZRU6T=- MS['CX_8_4\5!]V]0J9_<^/\`%8,?NBA6(CG]C[8_BQP='WT*<7%Q?U7ZGA4* ML_N?'^*PF/W10E^?G)7\`FA.#9JAM_P?ZN+P_:EQ:7A%[T57U&9Z22I)?:1> M='P_O3-,7!_!]LYPC_H\IW[0V-"OW[\2[Q*V/=WVL@Z MXK."?UU6=<2KN$MQ;6(DT(1Y4SJ*1;.I^2D)UTPD4H.G8!J\;@Y=%:/%0<.V MZ1$3\Z)D_3TII2MU77S*6GF"53RVATR802&@DAH#8C,YT#`1`@"24K6YEH;H M-[^NUNK:\458RZ%J'&G^LZQ6*RMS)GK@E;TI54X!T'+9\M^!YU)XUVJ]N=6-1U)Z&*?GJ-&DJLK"KW,K'6M M83V=..]LZ7I6ZCL>']51U4J_7R1DFLQE2C#,#"&=X MQ@1CE;M!Q,"`IF,@8G:A+]UMWCE0]WK>9_,245(UC92XR4=#W6HV/<`E)HH, M7!SQE:TFFX7;QJE5TX5PL!4'!DT9!HJJV.J@=;:1E:KM[62Y@EW*3$ MRGG9CM8[?E=`8C%I@<<07N;F'-/?:?-:6E[5%3["?LE>>BJRZ:BB=6GRS"41 M6,6LJD10S.8HZ8%C4D/!-6B7>0:1HS6KI*N=9P&;8];)QJE8VGD5S M-DC1=SJ8;N'E,E!ZZ34+'LZA$RL0^6`-XK"06$,C9"&R:2OLS3M]HKCF/JT< MDT<9;B`[#>6X.;^$T)S#!P2%F@;2!4&KS5_;C3Z\CI1A"DJ)65N^L4BC)[3% MOJ/=D7KD%53)*'C)5R1((IH8Y!`DF\0*8,A''3FJ+]*L%@K+JQX,TLA*WATQ MXZD.(\X_@@E3DY03O72QBHN-@8R.A8=BVC(B(8,XR+C6*9&S*/CF#=-JR8LV MZ12)H-6C9(J:9"@!2%*`!L#'(,QSYCW3)CBY[B223B23$DK&)B8KW][V?OAP MV"%K'J3UD:<-)E'RE8WQNE3=*),&RRK.FTY!"2K:HG9$%%F\33=(M%3S4I(/ M3$W"""9&Z8CO+*I)`90OL6BP7>^5+*:VT+YA)[4(,:.+GGJ@#ICP!."4-+MB MYU>MO5/4.M#4S)9I MJ/%B%(1=\JLJ4A"G`H=8Z;LDK3MFH[3*?G,L$N=\Y[B2YT-P).`Q@``LD"`6 MJ.0B6\TLC5&F?43/FI:U5;5`-74!<)Z*RD%0M7N& M:3&>XO%HE=Y72V99 MC!`.>P&+2W<7-B1EVN!PQ$#&]D<4Z%2]8TG6\0VGZ,J6`JV">ID59S--30BW+IJL4Q=H"4XXYZFR)].]TJ?)=+F@XAP+3\!@H""-H7T6][/ MWP[,1P0IO!R_?#@AT(6C^LCO"--FBB@INI[H5S#O:Q;L'9Z5M-`RS-]<"LIA M,A0:1;2(0.NO$,E7"A`7D'A$FC9/,PF,8"IGV+3^EKQJ.JER*&E<)!(S37`B M6P;R3A$\&@DGXTX,)Z%SE;XW=JN_UX;E7KKDZ!JKNA6<]6\&SAVAYP[-HX$+4_41KDTIZ5X1[+WMO M715*.6J3@R%,(RI9ZMI1=NF93H471L%UA43IPL(`4IA;D1*8P;YR%S$/;M6G M+Y>YK9=MMLR8">U#*P1WE[H-AY2>`*>&.,,$FIWGW?.W#UNMW]GK2QLU:?3@ MF_,9]'N7H$KBZ@-'!S,%Z[5C7"K"+@$]TBR<$W6=(=(*"CAPY,1$$.@=&>'E M)IPMN%>YL^[D8&'4E1&.2.)=NSD`PP`&,9FLRE`[R#E^]]\N+)`@GIRKYL8. M5B-3G#EZ7:4XQ*/[#`]O'/OC&`+I98?W#OTU#-'93.F]R#]\.*<@HE-[D'[X M<&Y(IO<@_?#@"%J;KCTR06L+2U=ZPDNFU3D*NIAPXHJ5=FW4Z?N'!"$S0TX9 M<$E7"#1I4;-`CSFLCK,%%T<]U4V?MZ;O,VP7J@NC"DDCMUHRL7E1$IA=E+@1) M4[-**DQ/TLX@((II'..PHXZ\J+E24UMFW9\T&B9),W,-[`W-$<8C9Q61$073 MCT]V6I/3E9.V=CZ(0YJFK:TC$4PQ5RYM6169-B]93+LH&-^73DH=9VN.8YK+ M&'/'&UTN%1=KC67*I,9TZ87'E'8!R`@!R"QG&)BLR;W(/WPXP8)%-[D'[X<) M!"F]R#]\.%@A3>X]O"'V0\O)@W;$BF]R#]\.""5+\?.21_>%4)P_PG[?<(Y_ MN<7A^EGBT_"'WHJOJ4STDE/EX.BB]Z/1RTF:8M@_P?;.?9#_`)O*=QH5_P#V MY>?K4WTCDUW:/2@9?."Z.K"F*ET/:MF]NT[IVMT\W)EE;FTG($Z1`K$?U-;> MJ(.+J4H-7Y6E.5J2C7L6Z=JMU6R2AD$U"G,NFF>R/"RHIYTK4MA-7W%;5R!W M;AVA!LQKBW$=9F<.`!!A$C9%/9C$101N\&UMQW>359;V6T]Z0W]LZCLI3%6U M54M9TH<]0UTZIF)8LYUPZF%J0I^#90M)T`A!+NT'3H7*J*BIQ14:@91->QM* M:;?H^15LNU_$^54O:UK'=5F8F&`>XYGOB`0(`@0(=@5(!",2B==QK']VE:6T MDIJ3N+>*@D-3T1UNE5Q+QRU/TPXM'%).GI&XVPB)AV8TOVBB"IJ.)QH9P_5W MSLR%:@+A!;3?$MVL:^O;9Z2WS?8KH9.Y#G=Z=_>$##*<`PP:,'$N,"&NS;!L M0F6%ZK1+]XK56K5M`.#:3(S7=;^L9KIB9<4^!,N?<1]/2\J MBU%/GN;25(!=_,H[TZW7`:2D6(S?]^=;'L&.,6MEM<(QXN:PF,-B=C!?_]#; M6['R(W6L&G4WKP=:\\7H75?3>G\_]CT7HGY3SO@W/*PR9_%G(>\] ME]WOCL\L4=?DFF^[:]!/JOP7JZ>FCT7]J*MZM]//6_I!ZPZS'K/I/77Y?U3S M_P#[IGY'-_!V8I75OM3VU-]K^K>O9&Q[B'=PAA"&^&WFHWQB(K?4>;R'AX.7 MZNS&LF,#%,0G=&_R>WKPZW?5KZ9ZRG7+?T]=(Z5V>Z1UPIVI]'G._D_0.W7] M_P#F?(ZWYO+\'S6-XO\`]JOLYIOVO#V-E/]GNL)_H'2.S_P"; MNON>Z1TG/R^;YO/9EBT='?:CV0?8WLSU7OG?XC+WF:#8[<T/6?6^]]CTKK+\KWLN#?VXWR3_%;(.X]E]UNR[/)# M!.Z_)?C?T=?^6C^N8E_FY^[/C1UU/Z.O_+1_7,'\W/W9\:.NJ'^;K_RT?US! M_-S]V11U^2R;07R'?-K^C#Y1_FM\>D]@^UW-<[D.?/\`9_R.]U]TKHG._VAS&[Y.[BF-3>O^W:_VEW'KW4S=Q#N_P"S9#+##LPC^%&. M*B?',8[4*GO$O46]9*J/3W\H7VV[-4EUMZOOI%]%'5W4J/5O1.H/S-UCT++I MN7E<[GO;<\;KI/[3^R)/LKV1ZMG=#O\`)WL8XQCC"/9CN3A&&Y"(F?YO?UJ] M[0^O)UWSY^L>N>G=:=)_LG3>G?E?/>'?\K&^R_XL9&]U[+[N&$-D.4,/@3^O MR7YO]'7_`):/ZYA_\W/W9\:.NH/\W7R_CH_KF#^;R'I5[,]"YU3^\_4OYKZ+SV_\`UCR-[/CSQX]1]O>^F>M>PO6( M];-DS1YQQCTHZV_+\2^D_P#UB_\`]B/_`,T_].(?^Z__`)__`--'6_!^)>C( M_):=$6ZU^5[Z!N&Z1UAZ8>B;F0Y\]TG\#N9>=LPYGVYB.[]@9^7=Q1UMV7XE MK'(_S>CI[OK?UWNM.?/T_K+IG3^DYCSG2^E?E//[WPM_RL\>RS^+.5O=^R^[ MAA#9#ERZ,$==>G_1U_Y:/ZYB3^;?[M^-'74_HZ_\M']NV[[4>K M^L=T[)W6S+FQCSBHWQPBC+CN<>>?+O8T#'FHU/)RX\N+X66#%"@;FW+/E^%[ MN%Q0J\CZ-["8\T)7&TGJC?SBFZ_5W.=I.Q=4=F-_F^SWK1]FV/I(Z'G_`&WV M&Z[SYSR>NNE9?A>9Q<]?[>_A-1=Y_8]ZW-MS>K9CW<>6?)RR9=T5/CW831WD M9!GGP!P[V*8Q4"OR,N/+/[;+/!BA3R/HWL&*50=SCSSY=[!CS2*_)RX\O_*Y M<&/E0J#P8I4*KO@/4Y]6"F/7=]*'HB]-%+=4^B;=[2]O>R-?]3]*Y MW9U/U)UESOZKS6-VT%]H?;4[[-]SZ_ZL^/>]G)GEQ\N;+#RIS8^;M6^]@.Q' MH*LSZ..MO1YZ*K?=@^OO[]]C>R<5V9ZXW?)ZTZFYGI&7]ESQK%T]9]I7#UN' MK??S,^79GS'-#E&,.2:8Q,=J^^JOLGV:FNV_4/9#H"_:+M5T#LWU7NATKKKK M?\U]7[G]2_5\_K$>KECFCNRPQCP@@1CAM6#;/^J%U15GH` M]73J'HZO;KT.^C+JCHO-K\_VL[$_D?,SV9XS[A[1 MZG>]Y&/X.??PAR3CFWKGWZ__`%&/66JGU-?2/Z+NT$AVCZ=U'V,ZSZP/UAZ& M-_\`/?8G+>Z'UMY>]GS7Y-S6.J=*_:;V-(^T/<^O9!EAFS0AAWN[/\[+\L5. MV.]&!:?(Y_)"U!T+TX]"]-E']INC]F/63]9+L=7/8;K?<_P`[#]B.T75W.?F M?JWIO-_GKG<:`[[?_;Z5F]6S^KOR]KU?U?.S/#S\^?N\T.MFRQ_5P3>MFY07 "_]D_ ` end GRAPHIC 6 g590927g73w25.jpg GRAPHIC begin 644 g590927g73w25.jpg M_]C_X``02D9)1@`!`@$`8`!@``#_[0FB4&AO=&]S:&]P(#,N,``X0DE-`^T` M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0`` M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`& M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4` M```!`"T````&```````!.$))30/X``````!P``#_____________________ M________`^@`````_____________________________P/H`````/______ M______________________\#Z`````#_____________________________ M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0` M````.$))300:``````!M````!@``````````````40```:(````&`&<`-P`S M`'<`,@`U`````0`````````````````````````!``````````````&B```` M40`````````````````````````````````````````````X0DE-!!$````` M``$!`#A"24T$%```````!`````(X0DE-!`P`````!P4````!````<````!8` M``%0```)E\K.$P]-U MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$` M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D M8N%R@I)#4Q5C+RLX3#TW7C\T:4 MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1 M`Q$`/P#J[L[,R+>K/H?9N8:JJ&U%T@-N]+]&UOYUONW+-ZAF58%[<;J_4;VW M$!UE-/J7FMI^BZ]^_P!-KO\`@Z_6L6I]7K:\3*SWY+Q6VH-;8]W`/J/K]W]I M>'UEC&M],_G^GM]+VJ3%`2E1[+HBR^C],P68F#M MPLCUA>1EHZY[[' M_0_D?^"J7U7Q% M5U#(?FX0D66L:[=['[OTC&_3=B[/UC^:?ZE7J4V,(HD+2]+TG(ZGETC*RO2K MIL)-+&L<'NK_`,#<_?9^A=:W])Z.Q_I_UUH2)B=>80_P!2-FZK/=_X`@IZ:0D2 M&@DF`.25A9E%)^MV`36TEV+>YQ@:EKJ=CC_*9N]J(YQS/K.[%O\`=CX6,RZJ MD_1=;:Y[#>]OY_I,9LJW?0W_`+Z2G7+C9632]LD>UY&YL_!KF;O\]8_3,_JV M=D9]#[:*S@W>BUS:GD.TW[G-=D?]^4LX##ZYTZW&&PYSK,?*K;H'M;6^^JUS M/H^K0^O^<_T=FQ5NA5/LZEUS;:^J,OEFW]QO^D98DIT.E=4MRLC,PLFMM>5@ M/:VQS#+'ML&^JUF[WLW-^G5^9_I+%I+F<2IN-E]4Z+DL9D;Z3F#)IMU++2Y MCL?&R>7T^G8UM%%O\R^KTZO](DI__]#K\FG$-W6/1R&-98QGJRU_Z.P//J[M MK/>US_\`1_GJKAXW5`RLXN52ZK/_[;KP5))+]-X`ZP:+!G M.J;=N'I.:"X;8$[VAU:J_5O&IHIR1BYARZ79%AL+Z]A;?/Z<-/L]F[^1_P!< M7SBX=;;YQK_`.Y7_6_Y[_`^JOG%))3]''$+>KX3K,_=GUXUC*6/ MIT?7-?KW7;2W]+N]+\^K_BD3[/2.IU#[63UEK'O+_3T=CES?T-M;?9]F8YS/ ML_Z7U/7KL_2_TQ?-J22GZ6LIJ'5:GY.2'9[Z[!@L=614QHV?:75-GWWO;LW[ M\CU/2_F6,K^T*ITO"+<[J+\+J1?I4LS'V]4\65 MGU`/6#FX[+)_F?6_1L?Z/\Q_-6?S=J^;$DE/_]D`.$))300A``````!5```` M`0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0` M;P!B`&4`(`!0`&@`;P!T`&\`$R0E*BP1,4)/_:``P#`0`"$0,1`#\`?KDI%E$1[Z5DG*+*.C6;E^_> M.#@F@U9M$3N'+E=0WNII((IB8QA\``-]`N_F/FUE3*&9V[JBW2TTC'S2>90U M>AH"6?PII.)"2024E9\K)9`SQ]+@'6*:FY6R1@2*&X'.=1NBV,%V?)/,R^`< M13F3&L`E9EXAW",DXA>1/%I+&F)-M&@J=X1F_.4&_P`1U]()^_MMN7?<'9KM MBLJAK#W3\Y/S&)7:?CBO(&WZ3.&,]./R#[-G"LXQ9"`!]+8=*,_A#590`=6B_&-&K9CF!R;G0.#[--V1` M^XF"(?I5X/'P]T(!O&`0/J#8-*04C1KB0S1F&6$PRF5LD2/5Y@]O%FP-*0N3%7%MM3L1%W9K"Z$1W$7$U)+"(_6*CDV^@D7PXEI5;D]AI): M3D%4E;>D"J:CURHFH'P#X=E"&4$IPW^D-)2[*3/^HTC0&@-`:`T!H#0&@-`: M`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H# M0?_0;1[EV:5Z'B6/QK"N11G,J.'321.DITK-JA#BU6F"^Z`F+\W=.$&OB(`= M`RY?'QTZL[(KBH9JW]YJ[^G8C]8-]5MC.#$O<9_"E<_TW2?WHC-31JLSDM[J MM@T&6U"A7:_R)8FD5.PVN1,8H&:P$2]DSI=8^!W!FJ*B;5+VB=02D`/$1`-* MF":%'[;7).V%37FH^L4%H?I,(V:?2T8(H98LO,V&L\U_!W%^#;E2$$6)X16V9$L]=M[Y88YJ>32('`Z*Z"BB2A1\##X[!FW'_`+H/+/DY;7--Q!Q@Q]/2,2LH_(DBD"RYNE-),%'"PE-Z:9@*;88+@,.26=).&D MU\[U?'54G2OTRPS#'%EF[.P5BQ:I&46DG&==;KU_B#H`G MT)](FZC=(P4T9=[N_)/!=^G,9Y-XU4*O6^OF;"]8_MA,OFZK9\V3>,'[!^R( MNS?,7K18JB:B9Q\Q*8"G*8H!M[!//[G3R/9!,XLX>5"2K`N%&HV^9N7.>M4@O(&7.#Q&63E8*,:M6Z;?I$AD551,;,X MIQ)`F1PJDDHJFB)C%*8P``A7;D3(7=,J\&^F:WA/BW:CLD%7!HBOVR]3,TJF MB43&!JSF7]&0>K=(;E226%500Z2%$P@`Q504IWIN8:3MTS7J>%89VU76;.F8 M4FX)KM'*"ADEVRR,E?W*R2R"I!*8I_>*8!`?'51;=A&5[@><<54#*[;-7'VJ M1>0*U'69G%%PY899]'-Y%+U2-G"BUV;(*K)AX")1Z=%P;.DZ7W%XML=>O9SX MU6QZF43$C[3ARW5ABN8OB"9WT#=YATEZGEN"?AH8(4Y/[DO+SBG.L8;E%Q7J M#MC(K*-XNW8ZMDQ"52>%$.I8\-)R+6\MSNDT0ZQ9.%&KL"^)R$*(#I[B?G$_ MG-A/EW'/241Z^@+G#MR.IW'UG!JVL;-J(D3-),/AEUVDW"E7.!!1LU6(M9QS6W]CAKC1*R^ M&.)F-:OD"?JSUU%2MB)Z,!B*"EFAO3<-(=C6R-GMS.U.WTG[?_`&YYOD^/M\WRN]/'X]\1,6Q%=R8GK-<+.U8F=8AV_%\1N;EMNYR+ M_C;,81&?\D`:7_S"?*V+GDW5[Q?A2WUL[@JCN&@XZVT^6*CON=*-G5[/9VS< MP@/@9PQ=^.W\OJ>1^U?A=S:^/%YO(V]ZF=TVWQ[V_&W#WL M3_Q!C[A;SUP7S@J#R:QA(NXJV5Y!D:ZXXL0(M[35U79"@1QT)',VF8)=R!TT M'[43)'$O2H5%7=(/E?GOMSR?V[R+=GG;<3LW5^&Y;C;=3\IUB?Q=%R^%N\._ MXWQ6VYF0$ M^WVC$^+.&X^/3L'D`:&B9G8SAH]'!&8+"FV2+*R66R0SMV!"@LM'PE.KKZ.; M'4^V9)LYL#HQ2CX`*IA#S'1>B[W1'FS$Q%U^)DYZ;?-HN&A8]Y*RTD]6(W9Q M\;'MU'3UZ[74$J:+9JV2,>]_P`GS;!\G@JLS#%Y M,J;*MBKTR`3^44:H`L!D5FTGL5W+% M=U8H.X>UPSQBFY4;IKN(64,@?Y58(P5`_,RD*^Z'"!P$!ZB=([E,8!DZA'RO M63(''?+RO9`Q;<7S,';)90"$E:])KQTDP<%*9,'L6^,V5;N4#_`)MP MW.9,X"4PAJF1ZC&]R99%Q[1<@1I>B/N]0K=M9$'S(UL4.SED$Q\_>(D[`!^L M-"6::`T!H#0&@-`:`T!H#0&@-`:#_]*R3.U@/:LU98L)U/5"5R';W*!M]P!G M\]?)L2%'Q]Q)FFF4OU`&K&3?DP:K?WFKOZ=B/U@WT6,X-+P2$)$(G,Y<&`QW#^4?J$3(M)2S]83.'[]8J90$YQV*0I2$`J9 M2E`DS,YJJN]MRVGN.?&:/H5`G/D>1<]3#^H)/FRGIR\5CUA%G7ODO$JE$5&K MY8SZ/C"K`!3I)R*BB1R*ID,'N?V_\%M^7\U?R>5M?+A\6V+YBF$WS,?"V>V$ MW4Z_&(F)B7:^)XUN]O3?N6ULLBOOT)*Z_0SU68U!)/B/R6N7$G/=%S73EE#F M@)!-G:84HD]"TTF1612L]:MM\?TW1UPZQUBL=6GD[%G)V;]JZ,XP]>DOZ*--M<%>ZE6+K M5WZ4K6[=7X:RP,D@8#(OX:PKT::3CR3S3+I6:)2RS50@*(/H^J_++%-/8YVD/6BY2.=$Y1`0-X[!" MF`L/*OEGBQ(93+'!VP3%51'K?V'!62XC*$@P1*'4JJ>F#!0\ZJDBF`G.J)DT M2%`1,8``1U2C>G'WF1Q[Y,M^C%U\8N;&B@HXD:).E^0WB,(AZ?Q1UJ\_,1R] M:-#*E*HZ9BY:%,8"^KOX:)1*'0&@1^YU?C%Y)?>[9-3,778>4GYM^TBH:%CGLM*R;]=-JQCXV.;J.WSYXY5,5-!J MU;)&.HQ< M#$.(J]%/F%,E&?A%7:O9UI\ MH8GJEC;3B:4K[\R?@'J%9RSYHX$FX^?3MIB4>&R[Q'#^2=MV$=_%F0?NU2(- M&3+'BKMVZ74'I31;-D)519=8YO`"E*(B/D&F.A3NG/A7.,'G.'E9R`IN4*>S MBWB#+T\GT&9H3R2%PW!R1U#M9@A3R3`I!Z3+)[D`_N^>A1MZ1D8^(8O)25?- M(V-CVRSQ_(/W"+1DR9MDS+.'3MTX.F@W;-TB"8YSF`I"@(B(`&JBO:R=Q_&< MI;G6.>.%#OW*F^,Q`'K?%;!,M*B2F4]$CF;R#(@$,SBU%A`I7R)'+$3#MZH# MX:BT>^?,O/H6OS9/ACCP&XD]4*V?DI"#9.D0W]`7Q:>%?!SM[?5Z-_;JE,;')^!BD;=?>WCER&HYBDD=/''<[N0>N3COON==RHJ8=_;[QM5O?MJW]YJ[^G8 MC]8-]%C.#A@>0?D#^C4<=SH$UO\`F#KB]F>8=!IYE3_*Z7@ZOK-FXF$4RREG MM-M>R;HI=]BG<,F3),WM$$`^K7W?]L.-99X/FW7MX\>'TBJ=9Y"1-NIO6H83&^! MIU^L]>ATP$1$0(A"L&R90\@*0`#PU^:OO;8LXWW5Y6RR*6W76W^]]MMT_P"T MR\?Y2R+.;O4RFD_6%F&O+.O&@6#[Y7X@\1_@V$XK.05(UA0*9153UDSE1GY#>/;[X%Q/$RM/;7;W+&T9ONC1(+ M-8$B?$-JTP4$KE:IU]XN`N%T#/`!5Z\V3,^6(3W0(DGNS,L%D>J@T!H#08M> M;=$4"F6R\SZY&T)3JY,V:674."9$HZ#CW$D[,)Q`=A]!N;;P$=_(!'PTD)L< M@L-9`G<+57G%=7CA1]R+S!D8TC%J)&!"+:.%U7M57:J'#U00D%H:9(F4W2F5 MFV:^F&QC:=EE?5V=-' M")P$BJ#ENJ8ARB&QBB(#J2L$;.,$2S>\K<`PKM(KA@MGK&;%=!4H'(NV"^PR M9TE2C[IR*D+L8!\!`1U4ZGIP``#8`V#Z-!SH(1\[^8$3P_P^>SH-FLSD.V.5 MX#'-==*"1NZE2(`J^G),J?YX82MMU"*K@385EE$4.I/UO4(%/?;&X\R_+?+U MWY8\BG+W(C*JSR3:(&T&!\VL^1#(HR`KNFBA/@SPE)C%VPMV)"$:$5<(%(0$ MVXIC/1:]9,OE*!0`I0V`/``#R#51SY^&@73[K_&%/!EFJO,K!+IUC^:>6YI& M7,E6.:(-'V]XW?/8F\19F0I`S6F/@E6TF4`!-PN=-0Q3'7<"=V7OU61]NKF0 M'+;$"RUG,R;98Q^LSA+\S:$(W0DR.43C"6UDT)L1LVGTFJP*I$`"(O$%BE`J M?I[P[K"=5"/W.K\8O)+[W;A^LU=2,H%_G$7D1R*K7&3"$!6>$^0KW`1./8%E M$7&-R?C2*86-BBW$J,JTC91\G(LD71?$$UB@H7VZJMVV/E[RMA(U=ZW[=V57 MRJ1#"5!+*5$>B<0`1``1KS.?D3_D(W.(^P-2I12AS#[B/(K-*KC".1*?)\9J M&_"F)"^O8L5RF51F#60:HY?1A#)`<&;=..*ZZ1(JJH0>D+15C_;` MXX<+XE);*6+[C1:_9^%>0;')1[5>:Q_,4BPUN0413,ZCWR)68:6Y'9%GI%@V>2-8Q,Z4 M@UW")%3QKJ6L\`Q=O&9C@(MW9V`*(>H78WHK*$WZ3F`0:.$0(41'P*4-_P`@ M!HA6+N!7*V*-DTI:X604 MA!Y+/U0ZU"MB&.9-FVZS$:-@*0HB;K.>>I5)751HSD/Q]QWR6QE.XSR+%I.V M,BW55AYA-!$TS59TB*A(^Q0#I0HF:R+!0^X@`@FX2$R*H&24.49/98+8<..5 M^0>!'(.Q\?LN2+YYB9K=I&EVZ)QWK#N621KSUX1)-/_1LC+`4`(3PNFACB:5$`$!`?$!\!_)HBH#.G$-[1.>G M&SE'AVG23F(L^0#0^9(VKPJR[.`?2T9(12N07R48@<&$;,1LFN64+L$[&J%$JD?,2;%0H^93M'J[\,,X5 M!R)1Z%)VD6B?^;(`;;IW0BK-&F\]_P`YK[I^U_)MW/#<_B5_7M;_`,O:^V*3 M];9^CU'A;XGB[FW_`'6WU^L1_!01KZ4[@:`T,\C^/:9Q^_QQV^^.$-*(&;OY MFK3%Z43.42G!KD*VS]UB#&`WO%ZX.<:CL.VVOS/]Y\FSE_='E]RR:VVWQ9[V M6Q9/XVR\;Y*_Y\W>F,JT^D46,:\RX(T"P??*_$'B/[FT_P!]K5J:C\W;RXBV M[DYQGR6C"QLTQW**S50$G2`B!@ZDS)JG*NM[;?#]OCJHQE`R'(BFDCF)6U?M#TZQ$R6\5`!-JZ,4`D]P(H/Q>QG,R,UZ_GXAXAJH-`:`T%4_=5R', M.,<8VXNT9=0;_P`H,@0E.30;FV41J,?+12DNNN9,WJ(-WDP\CT#B8`34:?%` M(])3!J=5AO[E#Q;@LA<+[-Q[J,4B4]3H,4CC-N"1/6;3V/F;=U644E"I_FG$ MM\M^"75`.HR;M7?[0ZN6)J7N[2.:5\4PU0;U(K$(!5'CR[O MW=D(NX,!0%11)A(((%$=Q!-$I?(`T1.'0&@AQW!*8UO?#/D)#N4"+?+L>RMP M;=1=S(O*(9&Y-EDA\R'!2#VW#S*80'P$=%@N+VELEOJ%S-H\&1RHG#Y/B+)1 M9E`#CZ*IAB7-CA%3I?9,LG.0""9#;=12K'`!V,8!([NDL`"FJ11,QB"6)UR)SY?QWEW@SR,F*K'6B M4K]QH\BVE*G=:ZNO&C.5U]TO(290+N)%&DBU*";QHIZR`+IK-U/4*0V[-,C7 M?!7E=' M_P`0<0LY72(<*LYDM1&LP[M`XIN6:U$=OT".6]%KUQO`(JE`Y!>,8@T)&+](@(>HSE)]%=,?,JB11 M#Q#0.":(-`:!2OO)TIK5N8R\TU0(E_$/&M.MSL2%`H*OVB\S3%53`'@)S-JF MB(CYB/B/CHJ]KM[64O<1$?'0+'HD2(A-,$52(2;,=_24.)1`Z"J9U)F9+SN%?=IH66DJ]C?D"HQQ[DY4B M<:WN2IV[*@W%VFF4J*[EVLLD2ISDB(@^(=`B/KR4("ARK2T&H=3'U MLX3I;==-)H['Q?*MXV_3+NNFZZZZ9QF7J:C$: M!8/OE?B#Q']S:?[[6K4U$U.QS^&S*/WX2G[A4'5T.BU'-.%<=Y^Q].8UR;`- MYVN3:(AL8")R$3()D.#*;A'_`*9UHR9C5#B9%",R2Z7\7H&/-^REC>'20')$%'(=1T7!MR$4N4.U3$R^P=3 M]L05]A4(N81./JN:T0:`$0#Q'P#Z]`O-DMGR6Y:<^,@92XKJT8J/$Y*.Q97[ M%>SE5K9)I=O9$+"O'-58J8CY.7+,OY,@*"F/IH)-E.H#>EM/54C/V8[T8^'\ M1..GC_\``Q/_`-BZ?4^A?[/E$S1Q?Y(OC7TD-!94A[)$948R52\:T:2E'Y+5 M'RE;#X1BF$3X;-&),>93@3$&-O%3AI\J* M9P4^!>/&:0R<4H8!-_YB(DRK-50WW*JB8!\M$EL\WV3?YH_T:DK&<$;>*OXP M^/O_`!#8V_Q`B=)RE#RFJ#0)T]U^'=Q7.G+SAR0Y49QCCV88'-OLLT''E8C# MG((A]@CZ,63\/`!(.BZ&;^#\DA*\/^-CIN82B`@"\1!-(ET0=A$ M.HCEDT3?3HL%0.VY#NYOF[Q\:LR'.=I;)"86$NX`FT@ZQ.R[HYQ*'@3T&1 M@\=@$1`/;H1U.H:(1^YU?C%Y)?>[.(\5!#WA+ZLPX`N_T#MJ=9&1 M]BB5E27OD%")J*C!NJI295VGXB@258R\VTCS_0155I(.0]@F`GCOTAM=#HM# M[IGX#\\_^VQ__BK1M!4AV,O]^N9/NE;?OA!Z'1:_W68=Y,<%\Q@R3,J>,7H4 MPNF0!$PLV&0JN9VIL`#N5N@0* M42)RD%,-#HR,/(IE'I]1!0GJ)B*:@'3,8@EJ6!YG=K7*W',)>^8X^.RGAUL= MP\7>LFIE;E2XXG6J)K7$M4@(^C6:(>_)LR^B!2B==)L7;<>C9/;8[C5PQ=;Z MI@C,<^ZL6(["\9URK34NL9S*8WE'SA-M%)%D%3"XO^31'_UK]NY_0'%=SI$7A-`"QF0:HR-ZY4^@IYNK`G#R") MC`&RATXLS`V_GLIM[-(T;;)P5Z5;^\U=_3L1^L&^JSC.#4O(S\/F9EZ[*,9N!E'\+,QC@CJ.E8MVNPD&+E/["[5VV42705+OYE,`[ M#MJMRV3!G=`EXXC&O9W@#3;0A$VXWFKH(I3`"4Q2E7F:\]W`=U%6AVY@ M`ONH',.L9MK%&,V=V+\C.VAPN[ALY)YCPME9#'>4)T@O;.^J3=A+1LX_43`@ M2UTQK)+PLQ&S:IRE]9RBLP,Y'J.L590WJ:]M]O\`WYY7P6Q9PMS;MY'!MG]- MMTS%UL:6WQ$X=IBZG2CL>+Y3?X]L;=]ORVX^L>DHC5#_`)`']D=>JY'[K1&U_\GAI_[IC^^_"/ M:+:S'O#F7>Y5_SW;JTRCI'HDEKK''&@-`L#WR3`/(3$I=_$N& MDA$/;L:[6O8?Y1`?YM-1-3L<'(/&_*28&#K+FZ2.8N_O`0]#HA2&$/H,*9@# M\FB]%U6B-*Y_P)CWDAC.>Q?D>+*]AY=+U6,@@5(DO7)I$APCK#!/%$E19RL< M MNUKB);%O$:FR\H=9>RYA?/LP6%RY,91PJ>UI-$8+K64W64!2KQK%8W4(_GUE M1_K#N65BVB*$N^!@\).HXQY!137J>5>14QS;54TP$YH*=,YEJR[7.`!T-XN: M0=H>8[J21=%Z,W[).9%;/A:_89DWJ:KS%]H2FX!NHH8%TZM>`JF$OV3/2@.VY=W4Z+M#_9-_FC_1J3D1G!&WBM^,/C[_`,0V-O\`$")T MG*4/*:HX$=@$?H#?^;0+&]V.L06:7RG)[$Z,O-5G&5I?<<P2<,X9G5W=JUBSR#ZRUV3$@CO\.+EV^9$V^R#'Q\PWJ+;=`:"J3O!YE9X M[XH/Z&V>H)V3,EABJLS9@KL]_9V'=M[':)!%(`'J;)$8-62PCL`!(E#S$-.J M]T'^R=QQD7EFN/)JP,E4(6(CWM`Q^9=(2EDIB0.V5MB$?.QZA1#V"&@F9H`1``W M$=@#VCX!H%!>[#GJ`S=RF?,*FZ;R-)3%.!)S*EF8JL+!G*0BI>,:.4A270 MH=>1?H5=RH0X`ZSQ]JN`.3 M9%Z!'MX&K9,J[2_M82.(5JQ@IT\M*14\TBFZ0$(S8K/(XCQ-,G2FB9T9-,I4 MR$*"%7]?Q$RS_8?_`(!/XA?95_WL?S?Z]]7VM1?XO__7B/U@WU6Z,X-2\C/P^9P^Z+(G[HRVHT6YP4]U6X:#]#5X[8N$G;%TX9ND M#=:+EJLHW<(F\?>261,11,WCY@(#H)-43F?R6QZFBUA\I3DI'H](%CK:#:W( M>F7P*BFXGT'TBU1*'@!45T@`/`-*842D:)25ONJYA8`FG:*!C^Q)D``,K'#/ M5YXJ/A[RBJDE-M`,/^2@4/JU*=T^$-S5WNN-)20CHV3PFY:'?O6C(7#"]I.B M)F=+IH>J"#BJM!,!!/OT]8;_`$Z43X=UOVC6AAF/FG"84D)2;Z8AV&IV,&8#Y$Q?(!K9',;B[->,AK*L M4DNVS+0#T1S*#+)OE"&@DS2KPJ-FY)O3;&E&L=[ M>5ZVVQM6V)7RM=HD(:QVZ5*9R@V!M!PA7#4TB[`RX&$GJ$]PIAW\-`M[W)B`F'J+S)P5D6M9/QSA;.$/9ZR^3S#BIR2:2A@$Q2&;'$@#L)S;;B]UI7U5I=PC/G)?F`$#1Z+Q@Y M"TW$=;DAG/A)[&-O_:*V3Y4%FC.1FVD9%O8Z-:1#5RL5NU2<.=U%CJJ*&'TR M),-3LL3XE+IN-ALT5B:6=T`4X]O'5IA8962DE86 M1@&1TDB+.RBU73:$`X@HYGZK:'"P-T%W!B**%0146,FB05%C@D0QQ(DF M'BHH8"[%*'F/AJHHVYT\MI?D#Q\NV%<:<3>5[N6N2]=3-/6["DW#0D2V@[-$ MV)1ZU!DO-2;Q^A<^Y M`*=/EEJ+Q)YD2=R6BWA8.-G,&R41$H3!FYP9#-R365DU4&";@2BH9LBY4$H; M`7QW!^10N+A_%'(W&.8,:91=\<,X3"=#R'4KP[C$<8W=LM)IUVPL9MPR1<'K MZB:"SPC0Q"G$IBE,8!$!`-M*]T,Y>4R!3/>%G-M%T)0$Z37#!72!3[>)2 M+JSS-0Y>KR$4RB(>P-/>%1?Y*\_>4.3J7*8XX]\1N1-`D+>E\CW-VX*N0#KH2$P_<"D)_?31!,`$!(&Q) MS5$2W!7D[P/S,OGGAR'\7,?F%=I-XP>.CEMZ]3>KE=/JU),Q!NE9V;51ND9F M]8G&327*0PM#E*H*@3VH/="XS39"P^5'UJX^Y`:%*G-T;+55GH9TP=D*`."H M2R$)*O M,3KUZY/N5`JLF[:,(I)N978#BBJY<%*.Y45!V*+$HKRC^#_*[GWFA+.'+=)7 M#>->I-"%H/Q&UO9U1!<[AI6J]!F*Z+7"N3&.+Y_*>B].N<5"M3E$H)P]5W+^%`&IX^LKVE8WAXQA$T/%U=/9+.X:*/F<81*%A`GI'#7F98K"#=08UI/X9>5J"5==/YHK^5:2-@D M6R/6/O"FQ6'8/`-/<+4Y!P[RGR5?+KD2Q%4,BU3!FR5:20!D]]$%%6B[90@K`)TSI&.J*C#469'[G5W! MIUI\#.5YWW1O\.I2I5-IU]/V1>%@E5@)U>WT-]O9I[K@A]G'E!W)^4T;(8YQ M%Q9R9A>GV)$\9)/CU^Q,;)),7("FNR098FKS\TL$D[2."A$;Q.I))QXL$52>^RCU M'1'0"`'K3E;?T^W0T;C*YMY4T2]?1LHC(1)G4(FT5DHZ1B$3%36.FFJD91, M3D$P'*PU(,Y8!Y#QG("/GGT?C#-.,%*ZK&HNF&9:"K17K\TDF[4(I"D-(R:, MH@V^#$%C)G_-"<@#]H-41FYX]O:F\OHEO9H5\TI6:*_'?`05K5044B9Z-2.J MNA7;>W:IG)%.X9BH80(L012$13JC!@7E'R#X3P+/#G.'%607M' MK)48BE9YI<6I>X%M!M]DVBYIL?_ M`-)N$/R?YW_^P-4!IZ/K?##'V8)CIVWZ/D/R+YSZP>0D]#JW]FK[)3NA!GOE MUGOF;7Y##?!7$^15*G9R+PUQSM98A2EP8PKD#)/(^L2THX1;Q[=^R./Q#A8Z M@E@**,U#2<2J!@W** M4BR79J`8/:7H6'?5E"Q_;\Y)9LX90$VEE3">8IKC39YET\+;8FF3CEO2;*Q4 M-%2DI'JO$FD2ZAWYF@)OD1<(F!5MZB(F4*JDK/1>RY&0[G?")C5AM)5D# MGA_3)W'W%ND(P$)$OKDW3:R=MK=?DW4PZBH9@B+EJ_DK/+/UP=KI*+,F#4W0 M+A99,B2D_,_(Q?\`!M__`$Z'^J?!_P"C)_J__I_L?Z#_`"?+ZM*(_]!_<0`0 M$!#7L5;8NHQ@-3EDGS=R_=-"23UDF MI#2O4=9-)'J%NJ!R`4J8I%!5MMNC"JWF_5)"_4.XT9T[6CF]QJL]5W#Y!,BJ M[)&>BG46JZ124$$U%6Y'0G*4P@`B&PZ-<32:J@;#VFI](3GJF9(AZ&PBFWL- M4>18@/L*=W'2\N!@V_K`B'Y-6K/YQHT?/=LGDI%"88S]@K.4!'I")LZS-4P> MS6@-!Y4I!0DVB#::AHJ7;E'0G3:(HD,(?6&@]?0&V@-2D:`TI&@- M*1H#5I&@XV#Z`T'.@!`!\!\0^O0&I2-`:4C0<;!OOL&_T^W^?5'.@ZB4H^92 MC^4`'ZO;]6@Q@U&I)WOS(U/JQI'K]3X\U?B1>^IOOU_%"T%?KW]O5OH,G*0A M?LE*78``.DH!X!Y!X!Y!H.V@-!UZ"?V"_P#9#_JT&N%<-8@7EAGU\58W6G3+ M?$&FEJ/6%)85Q'J%89$\69X*PF'?JZ]]_;H-C$333*4B9")E*4"E*0I2E*4` MV`I2E```H`'@&@[Z#__1?XT!H#0&@-`:#@?9^7_H'4G(<#[/RAJ3G*QU?,WF M7_,U9R75]M5B-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:` :T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-!__]D_ ` end GRAPHIC 7 g590927g81y89.jpg GRAPHIC begin 644 g590927g81y89.jpg M_]C_X``02D9)1@`!`@$`8`!@``#_[0H.4&AO=&]S:&]P(#,N,``X0DE-`^T` M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0`` M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`& M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4` M```!`"T````&```````!.$))30/X``````!P``#_____________________ M________`^@`````_____________________________P/H`````/______ M______________________\#Z`````#_____________________________ M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0` M````.$))300:``````!M````!@``````````````+P```-4````&`&<`.``Q M`'D`.``Y`````0`````````````````````````!``````````````#5```` M+P`````````````````````````````````````````````X0DE-!!$````` M``$!`#A"24T$%```````!`````(X0DE-!`P`````!W(````!````<````!D` M``%0```@T```!U8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4` M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P, M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X. M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`S_P``1"``9`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$` M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@) M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D M%5+!8C,T)E\K.$P]-U MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$` M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D M8N%R@I)#4Q5C+RLX3#TW7C\T:4 MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1 M`Q$`/P#J/K=]739319TFV[%S'O>QM=-MC66[:;\EM;JV6!GJ.=1M98J7^+7K M]F2R_I.5:^U[1]HQ7V.+G&MQ`OJ+["YWZ*US7_\`7O\`@UUG4/Z7TS_PT[_V MVRUYU]9<6_ZK?6ROJ6&W]#:\Y>.T:`R=N?B?V_4_]F*_]&IX>N/`=R+BI]37 MF'^,'JF<[J5%F/DVTX[J'FAE3WU@AMCJ_7=Z3V^IZ[F;J_\`@/27>WY[,W`Q M_L-DGJ8;Z%@T+:W-]2V_^1Z5'T/^['HUK@O\9U;*NJXE=;0QC,+:QHT``L<& MM"&`>L7XJ>_Z7T;#Z;36VK?9:UFUU]KWV6/)C>Y[[7/^FYJYG_&!TRK"Z95U M#!LNQ+FW,K>*;K&,>Q^[Z5;'AF]K_=O7:C@+E?\`&5_XG!_X9I_*Y-QR/N#7 M<^MOU>.9TZ_*Z<^ZCJ-(-K/0ML9ZL>ZRBR MNM[6O]5O\U^Y:L+_`!<78F?]KJS'V9.96YEU+[K;'_H2`&^DRQ[FM].YOZ3_ M`(VI=U1E49#KF4O#W8]GI6Q/M?M9;L_S+6+S//:?J?\`75N2P%N"]QN`''V: M\[.I,9,HRAUJX_P4^C]3Q,/*PWLS9;0P%[GM>ZLL@'] M(VVIS'LVM_E+%^J7U;=A85&9U&Z_)ZA8/4_376/;4'?0J;2]_I^HRO\`GG[/ MY[?_`(-:O47-RWX_3V$.9D_I;R((^SUEKGC^4W(L=3C_`/$VW+047$1&KW4Y M>.]Y^LNHMDMW8&&-S=")MZEJU8 MC.D]?/1:OJN[IF/714UE7[5;:WTP&$.^W58FW[3]O_PK/^[GZ3[0GQT-W6D? MLK=3_]#L/K!]:^A]/ZETNF[*K+VY)??M<'>DPTWXXMNVGV-];(J_L>I9_@U+ MZV]-H^L/U?>_`>S)OQC]HQ'U.#PYS1[Z6N9N_GZ7/K_K^FJF%_-N_K+5^K'] M&O\`^./_`%+5**N'!?$IRO\`%[CVU=`JSLQX%3]XP0^&^G0]_J.U/_!F=;:W%R*[OL^-Z=A8X$"PO>_TMT_3:WZ2]"ZM_P`@G^K5 M_P!56LG&_F&?#^*DA?O'][7^ZEW^F]5Z=U/&KR,'(KOKM:'-V.!(TU:YH/M> MS\]OYBY7_&5U7IW[(JP1D5NR;;V/%0>TN#&;G/L<)]K/S%I=%_Y:?_Q;_P`M M:I8'%GQ_O46/A]P5>^B$W^+O(QV_5>F;6#]-?^^O^^I-_BWR;,KHF M3E6O%MU^=?9:]L07OV/?$?1Y4O\`&'TC[=T3[;6W=?TTFX>=)$9;/^VQZ_\` MUA;71OZ*[_C'?P1NI_\`)N7_`,39_P!2Y+7WM-[4XWU&Q\IO0<7*S#NNMI8R MG2",:O=]B8[]YWIV>KO_`.$71*KTS_DW$_XBO_J&JTF9+XY7W4Y%+MOUFZB0 M"XMP,,[6\G]+U+0+F;OKOU3+K;9BFC!=CM=?E![A8RRHEFW%Q?69CW/ZQ39N MQ7XS*OLS+_YZ[])2Q=JS^G7?\55_U5ZYOZY_\L_5?_TXC_J4^'#?JK8;_P!U M3__9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0` M;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`A%R>WK+;'=S6]='O-`TNXMYB:FUHH9?59$$ MCT)!'40L/U`A*G.&P?DKU_R'?L=WS;O:Y-[C_)5UQ6_G&6P68E*_+66C+1_S M7Y,]<6=!1=LO&S+!\CWD34,T?(G$I1,(!H73=*VAJUK:W=KH-CDJT4JA30I9 M@KSE,93C,,#V@B'<(,QX#_)%E*V9QM>L.QF6;WD]?*C%6RXJL^3[M8+G-1ML MJT:NYG*>SF+5,2#Q&.GJVU.[0;)CV%=,#]H=ZYNL`]SMHV=MIUOK6D6-*B*) M"U5IHJ`HQD'DH`FK&1/1LJ2M9DXQ\Z:TRE72)DW2 M1C&046GT`'ZUL(%NWVOVOIUW9WFIZK:4:]2I(4TJ(KA4#."\F!`SNC*#QE3/ M(P\BR$X$KI!D?R*[L;(T/7^J[P[40(6)1]+6BT+Y^RT[2JU,@4/C;%.`R^VC M<7SI)L!46J'>0%G:Z1#&(4PF+.=R6FU-MZ1=:I<;;L7R2"J*%*;.V"KX,!S) MY`&%$"4Y0Z;B#0JL8M4I\I+[([KY8LU3DHF9/+Y*VVS7)Q5@D8IVB^!*P4>* MM4/19:"=+I`FM'.8]=LNV^J6!4!.)L]W^Y:M\+A!I&FT*50$2IVU$%01+NN5 M+@CDP:8.(EA)HM/E%AS9E##+QV=^DW14) M-.\:6BM+3S=`&Q102>"NF@GZC4TUZM2C;V]0N`"*M*G5`E/@* MBL%XXRE/GPA(,H6I\O6KFV>F^-4MD==-\MU)#&+>RQD!?*!<=DL#:=8K/:V,J5-FX1?^J\17=(G!=8AC@E;FQ-9T/7[S\HU?;.G"]*%D M=+>D`^7$JRY3)I8@K@0#@,)NJP.!&,+G_P`_.]7_`)G[6_\`R%RW_P!6\MG] M+;F564J5*G2!QG,BFJ@GM,S+"<-DSCKG/#,=8*.*9HP36\XL(9A8;GF:F! M!*OUV;O#F:LFX:?N%)!%!%3YPZQO9JZ>?1;`W`R"3[XA)`XF$A0$YNO0T_4J MFG/4>G;V]0L`"*M*G5`E/@*BMEXXD2)^(08)$*4>6W".^^@#M MM]WLN9GQ-BN0WLVGJ[')&1Z71GEB<;"99.E"MK58H^$6DA(>W`0YVB;T3E*8 M0*8X``B`#UY.-2T';MAI]_>KMJQ=J5%W"^A2Q*J3+P=D'@,90^#C31:EX[7I M\HYSUN;D"?J3J*D#2E_V_P`^SD?9)"*416]6S4Y&\,:-*L'ZR/5PQ/&_!*D, M9,R0D'IS--WN2O=+7IC2].I4G!$DM:`*@^5\A<$[E6:ED;(6Q+ M'(-7K]GFH:NWIE!T['SN%:7"%CGK>-LK:(=/5E&Q'B:Q4#JG,0"B8PC(]NV= MG<;8WQ<5[6F]Q1HT#39E5F0EWF4)!*DR$R)3@U\+07#D(F)<81"Q-UUG;>5S M??=#%.Q6RF2Z+0M7;'2JKB?`6/9Z!AUW4._@%7$OD`T-9(V?CWH.I)%-19^6 M-<.3"^21.X203:I#;MOK+;'VOMV]TG2*-6YO4=JM=U8R(8`)-2#PP`S`=TD` MDL8?F5"RXQ6ICK&9+:JS^(,V^61'6K+T]%RDC)*W=B:\05EC*KD1LYUG9.2O M`J:4E;%)=*Q.HD[$S51*%;N2,"N2',;LMK4]$H[^_3%(:Z,]*60Y""R$7!'B MDLB@>"(^RKB_:VL9 M8Q41DQ,YDW\_"ZF8$?V.JQR3<`76=WR#,Z:))!^:I(G;',`]G+?T+Q:E5F<`K7-8*QZ!#(SY+.'`9$?!";^/+[:\5WRG9*HLJX@;E0K+"V MVKR[8>BL?.0$@A)1SCM'\U5,CEN7O3,`D4((D,`E$0Y?]U:T+VVN;.YI9K:J MA1AU5A(_/\4.1ITZG;$53:_7C%.?:<9!.-R)5&$K(1:+HCPU*'>`=I@YC76]&KZ+J]_I5<]^BY`/#,IQ5A^TLC_!#+"1 MBQ/3G+](]83..-[`9=8X,Q);\CN8UQ8)**:-8ZH5)@8@2MYO]DD&E;H%#A2' M,7U9BYW&591K8`^A1R!AZ%`1#WZ9IKZC?V]H*@5&)+-R1%!9W/8B`L?@A2XF M$^O/MB5[A:J:)4^>ETK->GE?V'N>4K>DF9(MRRO>[5CJV9&LR*9RD4;1TE;) M9S\O;"`%8QI&[5,"I($*%_>U]ZNH5=RW%.GEM<]!::>2DBU%IK\(4#,>;3;B M86IF6Z1^-_#GTAST^ M[.&V*`ZW:?9>#?PP\WTYFGTCUAF<3IP>D>L"<#$\RZ"2WC.VK!9,BH)U&L+) M@H#VG(;V@/TAR9>WRLF\-$(/%V'^S>%H>]&=K54R*VBMI* MD`Z:D]#IJ$,'4IR'D&Y3E,`^P2F*/0>:NK9EHU2)SRGYH=C6%Z>[F'_2)QG' MGG$Z<'I'K`G$Z<'I'K`G$Z<'I'K`G%;]O-=*]MAK=EK`-E!%-KD*JNF$7(+$ M`_R2TL%49>HSQ!%-4Q3PUECVK@>T.XQ$S%^@P\[&@:E7T+6+#5:)QHO,CJIP M=?C4D08:1C,@M%C)[6M3##F"KJ")]A!CT?-&D7XY-K([;*N?2*H=%BBNMVB5(W. MOH.G_C=6M*=1@+9":E4^6E2&>HW^""!U8@:I<.9U')4'Z*<$0?LK(=IF>)@F:9,63Z`<8W/,65[(TJ>/J%#J35DG'8 M**`V;`JDT:MFK9$IW+^4E9%RBT9M42G7=.UTT4RF4.4!@]AIEYJ=Y;6%C2]2 MZJM)5'RDGH``22<``28(8F4`PNNL_C\\O&(+5OZ?'.:\=2T&UNT8\GJW(0-2 MON18S$T8;X=W+P(&M]6D7KF-:@S8.A$K[T$TD%E130232LNVUG=.P;^AM@7= MO6IL4.5@62F:IQ`;NL`#BP\,YD#$DK!*D#K%`H];P6?_`)S6V6CJSL",-^^_ M';:WP"3UN.T!,S!3,H)XY:OW(R`X^3JBE2&TJ-#%4"#.M:Y_P`.^5I?\-Z6>GZDOIYLWIS^GP^B285W\T?_T7^.%F7S"!`^]/?Z MA_)2'OVNI0?_`%1U\Y)]>(&D[0G_`$!_ZS7A3?1^"$V?-9IL&I.YEHD:S&IL ML49Y^/RQ0$V2!4(Z&?RLBK]NJ M;A.N[>HI5JYKZUE2J8S)`'<<\SF7`D\65H>4Y@.L$)_#A[EGJF0[EI?;Y,X0 MF2C2&1,3@Z<"9%G=H.)*>Y5]H"RW1$M@J\65\1-,O;ZL:J;IW*B(Q7W9T`U[ M6VW#;I]Y1E3J]J$]QC^RQRGL8W<53TR M*.L;:@(,+K<_43]2(G=A\@5]8^.:VLFH`).'N*<;R1[(J`@H5%Y9(=C6Q^B?FAZ-83F),R]1'FB<&9?,($3@S+ MYA`B<&9?,($3@S+YA`A(?\15J'^Z?8ZK[/U:/]*G;$L#1]N^'34^&B\LTN.8 MLG:JO:D5JS3N-2*TXLTM@F]ZL0]XJ,I79[*\ M$^BJ'$*%(04%GN)\,/Y*6<(G.(I+7.*7[.]-(Y9"A&F;>J5297FH.47LMJ3` MN?\`6U@J@\Q1<3D3"^"SYF+Y^SD=S+YA"(\\&9?,($!<\A?]QWPV#_W-V>_8 M7&G^GE@[6(.TO<$\1Z%O]NI"U\+1\_//5K38=!9.7@X]]-UG'^8,57W*E?CC MK>M.8SB95]'S#-5!$>KAFTFI>.>+B;\QNDU,X.)2HB8J?;.O;TMT(E2HJUJM MO42D3RJ$`J>PR#`=9RYP=/`GX(M#AOR(^/BT8GJ5AIVR^O=$J3:LQ1&5,LN2 M:-CVW%&XT M6[JU\YFZTW<.9XL'4$&?&<^>,C`*L#VPNO';)ZIN/+O;]UVL_ MU$>2C_-?2?\`U2U\Y+=Q?^HV?_V+_P!9KP9Y?!',?,%ID;EW*7*M%7:(IF,"9I`&IS^PG4/5L#W!; MO6J2L*_W=7H`3W6_O&D3]7-U@U,B(SW\=9`MF*;[3:&Z%(Y7435*/I'*?F1;G:]W;;GJ[=JME9:IFYX"D!G-8_5%+ M[P]!,<1#,L9[((VS;S'_5)]EX-_"8>5YF2&HG!`@9/F2_MG[7_%)XHSM*C^M=8^\,+^DFW-95U84:V'T3\T.QK!WW%>W=/-;6=D[C$C[T@^G MP(G+*QD<,!,8PI1."6\AD)BD?D2U38;EZC98PD+1DK:GT26SXU?O"%ZQ&1ZL M)Y.LN4%Q,46@21RJQKA0!#_UZQU',?0#9:@'.FV#?)X MAVJ(4ID9QFYUNP7?#61X:S0JTA5,AXQN#248J_6-I*`M=2ER+%36(4Q#D78R M;'L53$>@]IBF]@B'->5:-O?VE2C445+2M3D>A5A_9!P,/2^2-(/&>\6.[SHA M!;LBH*\`MBDUMFH2/356?DOD852!FL?L6R0+KK3!\AME(=H0`,*ZITC$ZE.4 M1R->;9NK;<];;APK"OE4G@4/>%0]GI]\]!.?`PR5DTN4=$T_Q+.8FPI$EO`^ MOEO)DS.9ES9(&.HJH[RMDMV%@LK`%5#G$\=3D%6U?C@`"$3BXALF4A`*!0\6 MX+^G?:E4_#"5C144:(Z4J?=4_"V+M]9B8(\>R+0\XD%$X($!>\A7]QWPV_Q- MV>]G_(N-.6-M+_Y#W!_L MW21T'31VU7(H@Y;.4%#$43.4Q#D,("`@/*[5F1E=&(<&8(P((X$'D1"8%]<_ M"QXS[U;'%QF-8X6/DWCD'3QA4KMDRCUE=8#=WU=2I]SA*TP2,;_63:M4$S_E M`>H\FMO[B[QM:`MZ6L,5`D"R4W:7[3(6/QDPK.V&,6\_D_U<_O\`:7O_`#_F?J?,._\`.];N]O.!^H-;_,OS M?\TK_F7^DS'-+ITR_5EE[(+,9SGC'__3?XXG*OE$"!;:%Y0J-YV@\HL'`2;9 MU(U[:ZM?,&A5DS.$@B<)X^QF^5%(#"?T4K5C63;]W3H!T>@^WV;YI=-_P"4?;!H]"F:S@D/X>.F9_XG^58+ M9&U"A4G!#24?2LO2;QJ`_6H,I>=HC2.7.7Z0(Z7@W12C^443>[E\^S:$6FO/ M*2&I2$^T*\_G'RP]3&!,5B_#?R+)IOI:6;EFYFW*OE$,1.#*OE$"!<> M:.4817C-VC%^Z1:@_KM0BV?JF`GQ#][D>GD:M4NHAW++&`>@![?9R9>W],MO M#1%4?UKK'WAA?TDVYJBN3Z-;'Z)^:'HUA.8ERKT$>:) MP95\H@1Z.S62`IM>F[9:9>.K]:K<6^FYZFDK#;8VSL+5K.JH_'5+6K4JD8C,4/='8@`7H2"1QA\#*LH?/YFG*OE$>>/' M3@RKY1`A"CSYZA%UUW$7RO5XD&.-MG&DC?V9FR:*3%EDV.<-D,I1*:2710BC MY](LIPYS@`**S*A2"/I&`NF/;+7CJN@"PK52;RR(0SXFF?XL_$`4^!!/C#Z, M2.V+!>`UYE?.\K+ZORB(N]9<3Y4J>UMS66(=5%S/>0M)QH[`P'06B[->H MR)M1$%/JR+4Q82E$S@XARO<];'3:=+64:6LUZ+6R=0A(9ZG6:H6ISZ51T@/( M"?.'50````]W,^95Z"&)QYX,J^40(G!E7RB!`7/(7_<=\-G\3=GOV%QIRP=K M`#:7N!AAZ%O]NI"U\+01C:C:'%6GF%[)G/,#V10JM>6CH]O&0+).3LUGGYER M5G#5JLQ:KEDD_F9-<1$H*+(HHHIJ++*)HI**%B6C:+>:]J%'3=/I*:[S,VP5 M5`F68RP`[`3,@`$D02@L90(O-GF/IF3=-$#8BO.1Y#G-7.M:DBTB92#]YD`E,G-.;``*RK\4?__4 M9NV=V)\K=CIB\:R/40/W"HF>V]SZCLK4]'H6FL/7M[,R]&H;:X0*0O M=-,M1"D2^B)@K\L.'*0)G"'`-%31;QS(VYOF_"F4J6 M61:^D#=@V0J5J^VA%943F,GW19T4.T2J+#[#&H?6-.T6S1JND[B2[&8`)Z-: MF\CSFRY,.?>!/(0T0O)HI7YR<&XESMJ26&M>2L08TS'5IQ2W8%7RQDZB8L;V MZ-,=XBR/C++#B-^) MDC<.Z]G=0(3SP>7;`"KS:$Y?)+A3R%9_V.=Y,VT@ M<`X2M,M6H]K0<97/<'4RD$K&-6,A+)13:OQ]TSI%R\I&K38R"CB0%/L=2)W` MAV`4$4[\VAJ&U-*T@6>AUKJYHJY-2HEK/92(IE.W(T_N\A9H1-@X3M$+(UBKY]=3$G M7W\$HLF]](I3(HB*I3IG(4Y??N+5]LWVD7=IK:W=*P<`%WM;I`K3[I#-1`#! MI9>IP@YK+'A#IF'=D=S;*M3HC,WCOON,I"6E8J*M=GK^?M;[S2:PT=O46DA: M#I(9(C+F[BHYL:G2M%4"1=*K M9ISF!Z2/*7;+CA."D.L+0>7]]Y.=HL>,:K:]:*-JKJ_`6R,EI&2R?M7JY%NK MG9TR.&E8^U-LG,JUZOPK=`[E8[6(;JK@JZ$%#KKF21!*X-AIL[1;QKBCK%6^ MUIZ9`%.VN"$7`OE44V8\!-B!AP`F9N+E'/&%\Z]IIEYG/P;LMPU1=F:S$8X* MU:[X:/*NG(H/4%`;MDPV&ZJ+K"7M(7\IA`.6I5W#I[4JJ_A[X34X_@KO##]Q M"\.O\$/[ALWLMT]OCGV+Z_Q=TSZ?^RGLYE_\GTC_`/66G\E=_P"XAB0\T>JF M]H=LD(YRK7/&OG24EBI'%HRG,[:?P,:NN!1%--S*,,[65TU2,?H!CE9K"4/: M!3?1QRGHVB%U%7=]LM/F11NF(^(T5G\H@27FT+W>3-EYHMH*5)(9ZRP,F_#UV8#GZ=-:;9<.)[S2YRAY<@ES,"UTHU&RC6MP- M8;#(7#6%TQA,[XME';:`W5T[M4XNV8W&(<+)1%9K&=9>QS\BH1,019L6KAVX M.($23.<0*,UW'KUE6T'6:2V]Z':VJ`9K2Z43*$8LU$*HZDD`6F2BPEWUJIZSUJ5DW4$QW)FRIBCZ)>3_`-M]0U&QW)0>VLZU M6U<9*P1&?*C'!V"@R"M(S/*8YPM,#V1^'\!V*<2XMTJ9JT_(&-;[E3(LRVR1 MFA"C7&I7"6HCJ?8>A0*%;#5J6E'4$_B*G'@N>/?`@NVDG;\GI@8%.>CW/U#4 M+S<;BO9UJ=C27TZ.=&4.%/?=,P$P6,LPF"H6`_'L@X74?=RN,[^2$81.H^[@ MSOY(&$3J/NX,[^2!A`C]ZZ)-V;?KQ/6F.?4UK&T7(>Q3N::V#(N/JG8WZ4O3 MI4HT M`,M.HRB3N>^RJ5IC'`N5!X"9!A2^%H[)Y,,+5[.VOM=J;O-=#P%D6%S3C"ZX M`OF2)B'BZNIG:LR+QS1ZRX;3*Z:<^[LC=5ZV08H)NW)CF]8C5SZ(HGYNS]3K MZ;JM6O\`EM6ZM&MJB5TIJ2WHL`'8$>'+@220.199S`3`PMUN#KUEW!6>J?N3 MMSGS2?<+9JE7"MJ9!T\^V-%Q\\F\EW.WM!TK4=/T2HC9+LH[@5)S<,PSJ@(PGZ@`Q$T) M!AR8(P&$HZ0RV*W74VXLGD%